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ABSTRACT OF DISSERTATION

THE LINKAGE BETWEEN TRANSCRIPTION CONTROL AND EPIGENETIC
REGULATION: THE SNAIL STORY AND BEYOND

Epigenetic deregulation contributes significantly to the development of multiple
human diseases, including cancer. While great effort has been made to elucidate the
underlying mechanism, our knowledge on epigenetic regulation is still fragmentary, an
important gap being how the diverse epigenetic events coordinate to control gene
transcription. In the first part of our study, we demonstrated an important link between
Snail-mediated transcriptional control and epigenetic regulation during cancer
development. Specifically, we found that the highly conserved SNAG domain of Snail
sequentially and structurally mimics the N-terminal tail of histone H3, thereby functions
as a molecular “hook”, or pseudo substrate, for recruiting histone lysine specific
demethylase 1 (LSD1) repressor complex to the E-cadherin promoter. Furthermore, we
showed that Snail and LSD1 are both required for E-cadherin repression and EMT
induction, and their expression is highly correlated with each other in multiple human
tumor tissues.
Our findings have important clinical ramifications in that compounds mimicking the
SNAG domain may disrupt Snail-LSD1 interaction and inhibit EMT and metastasis. In
the second part of our study, we designed a batch of compounds based on the structure of
the SNAG domain and are currently screening for candidates capable of competing with
SNAG peptide for LSD1 binding. In addition, we applied a peptide pulldown/mass
spectrometry-coupled analysis to identify SNAG-interacting proteins, among which are
many chromatin enzymes and modulators. Functional characterization of these proteins
will help to elucidate the Snail-mediated epigenetic regulation process.
In the third part of our study, we found that Snail interacts with poly(ADP-ribose)
polymerase 1 (PARP1) through a potential pADPr-binding motif and is subject to
poly(ADP-ribosyl)ation, which can stabilize the Snail-LSD1 complex for enhanced
PTEN suppression under DNA damage condition. Our findings added another layer to
the delicate Snail transcriptional machinery, and indicated that PARP inhibitors may be
applied in combination with conventional chemotherapies to target cancers with high
expression of Snail and LSD1.

In summary, we demonstrated that Snail cooperates with multiple epigenetic
machineries to induce EMT as well as survival of tumor cells. Our findings contribute to
a better appreciation of Snail-mediated epigenetic network as well as diversification of
therapeutic strategies against cancer.
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Chapter 1: Introduction
1-1 Overview of epigenetics
Coined as early as 1942, the term “epigenetics” is undoubtedly showing its popularity
nowadays 1. While the field of genetics focuses on the study of inherited genes,
epigenetics deals with the issue beyond the genetic code: the epigenetic code, which has
been introduced to describe the determinants of gene features other than the changes in
DNA sequence

2-4

. More specifically, within this immense field we are looking into

processes such as DNA/RNA methylation, protein modifications and chromatin structure
remodeling, and digging out the underlying mechanisms of how they work in cooperation
to regulate gene expression. With the advancing knowledge in epigenetics, we have been
able to better appreciate the diversity and delicacy of gene expression regulation, which
makes every single creature in one species distinct and unique.

1-1-1 Epigenetic regulation is a dynamic process

1-1-1-1 DNA methylation
The epigenetic information is maintained/regulated through a dedicate system
highlighted by DNA methylation and histone modifications

5-7

. While histone

modifications generate reversible local chromatin structures, DNA methylation provides
reinforcement as well as establishment of gene silencing by keeping chromatin in a
relatively stable long-term repression state 6. At the molecular level, DNA methylation
refers to the transfer of a methyl group to the 5 position of cytosine on CpG dinucleotide.
It was first described in 1948

8

and has since been proved to happen in 60-90% of all
1

CpG sequences in vertebrate genomes, with the exception of CpG islands found in the
gene promoters 9. During normal development as well as disease progression (more
discussion below), the CpG islands on specific promoters become methylated, keeping
the corresponding genes from transcription. Mechanistically, promoter methylation
confers the gene silencing effect by either directly impeding the approaching of specific
transcription activators to the promoter area or facilitating the recruitment of corepressor
complexes through methyl-CpG binding domain proteins (MBPs) 10,11.
DNA methylation is catalyzed by two classes of DNA methyltransferases, namely de
novo methylase (DNMT3A and DNMT3b) and maintenance DNA methyltransferase
(DNMT1)

12

. As their names imply, the former group can create methylation on

unmodified CpG sequences and is thus responsible for the establishment of DNA
methylation patterns

13,14

, while the latter is required for the preservation of DNA

methylation through replication

15,16

. Although DNA methylation has long been

considered as a stable epigenetic silencing mark, it is in fact under dynamic regulation
through passive or active mechanisms. Passive DNA demethylation may occur in absence
of the maintenance activity of DNMT1 during DNA replication. Active DNA
demethylation, by contrast, involves enzymatic removal of the methyl group. There are
several potential mechanisms of active DNA demethylation, including (1) DNA
glycosylase-mediated 5-methylcytosine (5meC) excision

17,18

, (2) cytidine deaminase-

mediated deamination of 5meC to thymine followed by base excision repair (BER) to
correct the thymine/guanosine mismatch

19,20

, (3) direct removal of 5meC-containing

DNA lesions through nucleotide excision repair (NER) 21, (4) elongator complex protein
3 (ELP3)-mediated paternal genome demethylation
2

22,23

, and (5) the ten-eleven

translocation

(TET)

family

proteins-mediated

hydrolysis

of

5meC

to

hydroxymethylcytosine (5hmC), which could be subsequently converted to cytosine 24,25.
While extra evidence is still needed to confirm the mechanisms of active DNA
demethylation as mentioned above, it is possible that a certain mechanism dominates in a
biological context-dependent manner.
1-1-1-2 Histone modifications
In the eukaryotic nucleus, DNA is packaged with core histones and other
chromosomal proteins to form chromatin 26-28. The basic repeating unit of chromatin, the
nucleosome, is composed of two copies of each of the four core histones, H2A, H2B, H3
and H4, wrapped by 146 base pairs of DNA 26-28. While it has been over a century since
histones were discovered, only recently did we begin to appreciate their roles in
transcription regulation

29

. Of note, the “histone code” hypothesis was introduced one

decade ago suggesting genetic information be regulated in part by histone modifications
2,30

. Structurally, each histone protein contains a central globular domain flanked by N-

and C-terminal tails. The histone tails are subject to a wide variety of post-translational
modifications, such as phosphorylation, acetylation, ubiquitination and methylation, as
well as their counterparts, i.e. dephosphorylation, deacetylation, deubiquitination and
demethylation. Carried out by the corresponding enzymes on specific amino acid
residues, these modifications function to affect histone-DNA affinity and chromatin
structure, and provide docking sites for nuclear proteins with further chromatin structure
modulation or transcription regulation activities, in such a way that they present and
orchestrate epigenetic information to manipulate gene expression 31.
3

Unlike DNA methylation that is generally linked to gene silencing, the much more
variable histone modifications could direct gene expression to go either ways.
Particularly, acetylation and methylation, as well as their counterparts, i.e. deacetylation
and demethylation, play essential roles in conferring genes with specific transcriptional
potential

5

. Histone acetylation and deacetylation are mediated

by histone

acetyltransferases (HATs) and deacetylases (HDACs), respectively. While acetylation
introduces an “open chromatin” state and increases the accessibility of transcription
complexes, deacetylation does exactly the opposite to impede gene transcription

32

. In

terms of histone methylation/demethylation, things become more complicated. For
example, methylations on histone H3 lysine 4, 36 and 79 are generally considered as
transcription activation marks, whereas methylations on histone H3 lysine 9 and 27 are
linked to transcription repression

33

. In addition to acetylation and methylation, histone

phosphorylation has been demonstrated to affect chromatin structure and play a critical
role in cell division and apoptosis

34,35

. Histone modifications are dynamically regulated

by specific enzymes and their cofactors

36-40

. One typical example is histone

demethylation carried out by two classes of demethylases: the Jumonji C (JmjC) domaincontaining proteins and the amine oxidases such as LSD1 (more discussion below).

1-1-2 Crosstalk among DNA methylation and histone modifications

There are abundant histone modifications particularly clustered on the relatively
unstructured tails, making it possible for these modifications to influence one another.
For example, a lysine residue is subject to different modifications including acetylation,
methylation, ubiquitination and sumoylation, and these modifications on this particular
4

residue are mutually exclusive. In addition, a modification on a certain residue may either
hinder or facilitate the access of chromatin enzymes to the adjacent residues 41,42.
It has also been established that DNA methylation and diverse histone modifications
are interdependent events with specific hierarchies and/or feedback loops

6,43-45

. On one

hand, a specific histone modification pattern would predispose DNA methylation.
Basically, as an initial step in gene repression, removal of methylation on histone H3
lysine 4 (H3K4) releases the inhibitory effect on the approaching of DNMT3a and
DNMT3b to the nucleosome, therefore presetting a welcome environment for de novo
DNA methylation to take place

46

. Subsequently, deacetylation of histone H3/H4

facilitates the binding of histone methyltransferases such as G9a and SUV39H1, which
use different mechanisms to further promote the recruitment of de novo DNA
methyltransferases (more discussion below) 6. On the other hand, once the pattern of
DNA methylation has been set, it serves as a template for the reconstruction of epigenetic
state during the cell differentiation process. Indeed, there are previous studies
demonstrating that methyl-CpG-binding domain proteins (MBDs) residing in the
chromatin region mediate the recruitment of HDACs; in addition, DNA methylation
predisposes H3K9 dimethylation (H3K9me2) while excluding methylation on H3K4 47,48.
The detailed mechanism of how these epigenetic events influence each other remains
incompletely understood.

1-1-3 Epigenetic regulation in development and disease progression

During development, the phenotype of each individual is determined not only by
genetic information, but also by epigenetic parameters. For the appropriate execution of
5

developmental programs which seek to reach the balance between dynamic cell
reprogramming and stable homeostasis, it is necessary that the whole epigenetic
machinery function properly. Epigenetic regulation is involved in events such as genomic
imprinting

49

, X-chromosome inactivation

terminal differentiation

53

50,51

, cell lineage restriction

52

and tissue

. As a typical example, the Polycomb group (PcG) and the

trithorax group (trxG) proteins function to maintain the spatial expression of Hox genes,
which are critical in the determination of anterior/posterior patterning during early
embryonic development. PcG is composed of two complexes: Polycomb repressive
complex 1 (PRC1) and Polycomb repressive complex 2 (PRC2). PRC2 represses Hox
genes expression by exertion of histone H3 lysine 27 trimethylation (H3K27me3) and
recruitment of DNMTs, while PRC1 imposes silencing through chromatin remodeling
inhibition and histone H2A ubiquitination 54-56. As the mechanistic counterpart of PcG,
trxG binds the same chromosomal elements and maintains Hox genes expression through
its component Ash1, which deposits transcriptional activation mark histone H3 lysine 4
trimethylation (H3K4me3)

57,58

. It has been indicated that PcG and trxG cooperate to

regulate the expression of critical genes involved in embryonic stem (ES) cells
maintenance and differentiation 59,60.
The epigenetic landmark is regulated in such a sophisticated fashion that disruption of
the balance of epigenetic stage, either at the genome scale or even restricted to a certain
gene, is usually the cause of many diseases, including but not limited to diabetes
asthma

62

, neuronal disorder

63

and cancer

64-66

61

,

. The very first case was documented in

1983 when researchers found an aberrant level of DNA methylation in colorectal cancer
patient tissues

67

. Since then, a growing number of studies have demonstrated the
6

contribution of abnormal DNA methylation to human diseases

68

, a couple of cancer-

related examples being (1) promoter hypermethylation and therefore silencing of tumor
suppressor p16 frequently found in multiple human carcinomas

69

, and (2) promoter

hypomethylation and aberrant activation of HRAS oncogene in primary human cancers 70.
Besides DNA methylation, the far more diversified histone modifications play crucial
roles in epigenetics and are often misrepresented in human diseases. The disease-causing
histone modification patterns are reminiscent of anomalous chromatin regulator activities
71-73

. For instance, overexpression of histone lysine specific demethylase 1 (LSD1) has

been correlated to malignant progression of prostate cancer, neuroblastoma and estrogen
receptor (ER)-negative breast cancers (more discussion below)

74-77

. In a recent study,

Jiao and colleagues identified common genetic mutations in pancreatic neuroendocrine
tumors, including mutations in MEN1 that encodes the transcription factor Menin being
able to recruit the histone H3K4 methyltransferase mixed-lineage leukemia (MLL)
complex; and mutations in ATRX and DAXX that encode proteins to form a complex
harboring chromatin-remodeling adenosine triphosphatase activity 78,79.

1-1-4 Epigenetic modifications as therapeutic targets

As mentioned above, epigenetic deregulation is almost always associated with human
diseases. Accordingly, epigenetic therapy, which aims to correct these defects by
targeting specific epigenetic regulators, has emerged as a promising area of
pharmacology given the fact that unlike genetic alterations, epigenetic aberrations are
potentially reversible 80-82. In 2004, Azacitidine, with the trade name Vidaza, became the
first FDA-approved epigenetic drug to treat bone-marrow cancer and blood disorder 83. It
7

is a cytidine analog and functions as a potent inhibitor of DNA methyltransferases. In
addition to Azacitidine, cytidine analogs with similar working mechanism include
Dacogen 84 and Zebularine 85. Notably, DNA methylation inhibitors in combination with
conventional chemotherapy drugs have shown promising anti-cancer effects

86-88

. The

enhanced tumor cell killing effect may lie in the reactivation of proapoptotic genes
through reversal of promoter DNA methylation. Despite the clinical success as mentioned
above, inhibition of DNA methylation could have controversial results according to the
following concerns: (1) global decrease of DNA methylation following treatment of
DNA methylation inhibitors may unexpectedly activate the expression of oncogenes
and/or cause genomic instability; (2) since DNA methylation inhibitors exert their
function during DNA replication, they are cell-cycle dependent and may be not as
effective in treating diseases without rapid cell cycling; (3) DNA methylation inhibitors
have shown certain toxicity and the level of DNA methylation may bounce back after
drug withdrawal. Together, these limitations leave room for future improvement of
therapies.
Besides DNA methylation inhibitors, innovative drugs targeting enzymes involved in
histone modifications are under development. Vorinostat (Zolinza, formerly known as
SAHA), for example, is a histone deacetylase inhibitor that was approved by the FDA in
2006 to treat the rare cancer cutaneous T cell lymphoma (CTCL) 89. Since then, research
has endeavored to investigate more histone deacetylase inhibitors, several of which have
been

through

clinical

or

preclinical

tests

82,90

.

Furthermore,

novel

histone

methyltransferase and demethylase inhibitors are currently under intense investigation
and will hopefully enter clinical trials in the near future (more discussion below)
8

91,92

. In

summary, the importance of epigenetic regulation during development, as well as the
dynamic nature of epigenetic landscape per se, renders epigenetic therapy a promising
research field for the cure of a variety of diseases. With the advancing technologies such
as genome-wide sequencing in combination with chromatin immunoprecipitation (ChIP),
bisulfite conversion or RNA profiling, more comprehensive data will be attained for the
identification of critical epigenetic regulators as therapeutic targets.
1-2 Overview of the zinc finger transcription factor Snail
Snail is the leading member of the Snail family of zinc-finger transcription factors,
which also contain Slug (Snail2) and Smuc (Snail3)

93

. It was first identified in

Drosophila as a suppressor of shotgun (an E-cadherin homologue)

93,94

. Snail plays a

central role in morphogenesis, as it regulates the formation of the mesoderm and neural
crest in species ranging from flies to mammals 93-95. Absence of Snail is embryonic lethal
due to severe developmental defects at the gastrula stage 96.
Structurally, Snail family members share a highly conserved carboxy-terminal region
containing four to six C2H2-type zinc fingers, which recognize specific E-box sequence
(CAGGTG) present in target gene promoters. The amino-terminal region of all vertebrate
Snail family members contains an evolutionally conserved SNAG (Snail/Gfi) domain,
which along with the zinc finger region accounts for the transcriptional repression
activity of the proteins. For Drosophila Snail, while the SNAG domain is absent, it
contains a consensus PxDLSx motif that can interact with a co-repressor CtBP (carboxyterminal binding protein) for the exertion of transcription repression 93.

9

1-2-1 Snail plays essential roles during cancer development

1-2-1-1 Snail and epithelial-mesenchymal transition (EMT)
EMT is initially recognized as a process vital for mesoderm formation in Drosophila
and mammals

97

. During EMT, epithelial cells lose their ability to adhere to each other,

gain fibroblast-like properties and become more mobile

98-100

. The migratory nature of

these transformed cells is reminiscent of the characteristics of metastatic tumor cells.
Indeed, there has been strong evidence suggesting that EMT is an early event during
101,102

invasion and metastasis of many carcinomas

. EMT of tumor cells can be induced

upon receipt of microenvironmental stimuli such as tumor growth factor β (TGF-β), Wnt
and tumor necrosis factor-α (TNF-α)

103-107

. It confers tumor cells not only with the

capability to migrate and invade, but also with stem cell-like properties, which largely
account for immunosuppression and tumor recurrence 108-111.
As a commanding cellular event during embryogenesis and tumor progression, EMT
has been a long-time research interest in the field of molecular biology. A hallmark of
EMT is loss of E-cadherin expression

112,113

. E-cadherin is a cell-cell adhesion molecule

that is involved in the formation of epithelial adherent junctions

114

. Along with several

other transcription factors such as Slug, Twist and ZEB1/2, Snail is well known for the
role of E-cadherin suppression and EMT induction 113,115-118. Remarkably, Snail protein is
overexpressed in both epithelial and endothelial cells of invasive breast cancer compared
to normal tissues

119,120

, and its expression correlates with the degree of metastasis and

predicts a poor outcome of patients with breast cancer 121-123.

10

1-2-1-2 Snail and tumor cell survival
In addition to EMT induction, Snail regulates cell cycle progression and survival.
Snail expression has been demonstrated to confer chemoresistance on breast, colon, lung
and pancreatic cancer cells

124-127

. Snail protects cells from death probably through

transcriptional repression of proapoptotic genes. For example, Snail has been
demonstrated to repress the transcription of a subset of genes required for p53-mediated
apoptosis

128

; Snail promotes cell survival against genotoxic stress through BID and

caspase-6 repression

129

; Snail also directly inhibit PTEN transcription to render cell

resistant to γ radiation-induced apoptosis (more discussion below) 130. Interestingly, Snail
has been shown to block G1 entry and G1/S transition during cell cycle by repressing
Cyclin D2 while maintaining high level of p21 expression

131

. This seems paradoxical

since the cyclin-dependent kinase inhibitor p21 is previously known as a proliferation
inhibitor and plays an important role in preventing tumor development

132

. Recent

studies, however, found that in addition to its function as a tumor suppressor, p21 also
exerts oncogenic role by inhibiting apoptosis

133

. Based on these findings, it is possible

that Snail enhances p21 expression to block cell cycle progression in response to cellular
stress and damage, which permits DNA repair to proceed for tumor cell survival.
Together, Snail plays multifunctional roles in tumor survival and progression. In fact,
it not only promotes EMT and inhibits apoptosis, but also induces immunosuppression 134
and maintains the properties of cancer stem cells (CSCs)

128,135

. As Snail remains an

intense research interest in the field of cancer biology, more mechanistic details will be
clarified for a thorough understanding of its roles during these processes; furthermore, the
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association of Snail with some yet-to-known cellular events could also be discovered in
the near future.

1-2-2 Snail is under dynamic regulation
Snail is high unstable with a half-life of around 25 minutes 123. The activity of Snail is
mainly dependent on its protein stability as well as cellular location. Basically, glycogen
synthase kinase-3β (GSK-3β) can phosphorylate Snail at two consensus motifs to
respectively mediate its nuclear export and β-Trcp-mediated protein ubiquitination and
degradation

123

. Activation of receptor tyrosine kinases such as epidermal growth factor

receptor (EGFR) and fibroblast growth factor receptor (FGFR) can initiate signaling
cascades leading to GSK-3β suppression and Snail expression 136. In contrast to GSK-3β,
p21-activated kinase 1 (PAK1) phosphorylates Snail at different lysine residues in favor
of its nuclear localization

137

. Furthermore, several critical pathways are involved in the

regulation of Snail. (1) TGF-β induces Snail expression through SMAD signaling
activation 136. (2) Ras enhances Snail expression in a MAPK and phosphatidylinositol 3kinase (PI3K)-dependent manner

138,139

. (3) Notch signaling mediates Snail upregulation

through direct binding of the Notch intracellular domain to Snail promoter. Alternatively,
Notch signaling can induce the recruitment of hypoxia-inducible factor 1α (HIF1α) to
lysyl oxidase (LOX) promoter for transcription activation. LOX then mediates Snail
oxidation, which masks the GSK-3β-dependent regulatory motif
directly bind Snail promoter for transcription activation

141

140

. (4) NFκB can

. Alternatively, NFκB

signaling can induce the transcription of COP9 signalosome 2 (CSN2), which functions
to block the interaction of Snail with GSK-3β/β-Trcp and stabilize the protein
12

103

.

Currently, an interesting notion is that histone-modifying enzymes can switch their
substrates from histones to non-histone proteins such as transcription factors and
enzymes (more discussion below). It remains to be seen if Snail is subject to
modifications by some of these enzymes, and how these potential modifications may
affect its protein stability as well as its function as a transcription repressor.
1-3 Linkage between Snail-mediated transcriptional control and epigenetic
regulation: hypothesis and research aims
As mentioned, overactivation of Snail is intimately associated with the development
of a variety of cancers, many of which may concurrently harbor aberrant epigenetic
landscape. It will be interesting to find out if there is any linkage between Snail-mediated
transcriptional control and epigenetic regulation during cancer development. According
to the chromatin “reader and writer” idea, as a transcription factor, Snail is able to “read”
its target gene promoters using the DNA-binding zinc fingers; however, Snail does not
have chromatin modulation activity and falls short of “writing” epigenetic marks on
either DNA or histones. It is hypothesized that transcription factors (as chromatin
readers) can cooperate with chromatin enzymes/modulators (as chromatin writers) to
regulate gene transcription. Indeed there have been emerging research data demonstrating
that Snail can recruit different chromatin-modifying proteins to its target gene promoters
for transcription repression (more details below). However, the specific mechanisms
governing these processes remain only partially understood, a key question being how
Snail orchestrates multiple epigenetic events to promote tumor development.
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Clearly, exploration of the Snail protein interaction network will help us better
appreciate this typical epigenetic story. To achieve this goal, we recently applied an
affinity purification-mass spectrometry coupled analysis to identify Snail-interacting
proteins (more details below). Among the proteins we identified, lysine-specific
demethylase 1 (LSD1) and poly(ADP-ribose) polymerase 1 (PARP1)

142

are two

interesting candidates due to their chromatin-modifying roles and, more importantly, their
involvement in tumor development. Based on our preliminary finding as well as those of
previous studies, we hypothesized that Snail cooperates with LSD1 and/or PARP1 to
exert its functions such as EMT induction and apoptosis inhibition. Two of prominent
Snail target genes are E-cadherin and PTEN, which respectively represent an important
indicator of EMT and cell apoptosis. Through our study, we aimed to clarify how LSD1
and PARP1 are potentially involved in Snail-mediated E-cadherin and PTEN
suppression, and tried to exploit the underlying clinical indications for the development
of novel epigenetic therapies.

Copyright © Yiwei Lin 2012
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Chapter 2: The SNAG domain of Snail functions as a molecular hook for recruiting
LSD1
2-1 Introduction
As mentioned, EMT confers cancer cells with the distinct advantages of invasion and
metastatic dissemination

99,143

. Interestingly, EMT is a reversible process

144,145

. When

cancer cells disseminate to distant sites in the body, they no longer encounter the signals
that they experienced in the primary tumor and can revert to an epithelial state by a
mesenchymal–epithelial transition (MET). The phenotypic plasticity of cancer cells
during EMT/MET indicates the involvement of an epigenetically regulated differentiation
program, which remains to be elucidated 146.
Snail is a master regulator of EMT, remarkably through transcriptional repression of
E-cadherin

93,94

. For vertebrate Snail proteins, the SNAG domain at the amino-terminal

region is required for their repressor activity 93. According to the chromatin “reader and
writer” idea as mentioned above, Snail may cooperate with chromatin-modifying
enzymes/cofactors to repress its target genes transcription. It was hypothesized that
SNAG domain functions as a linker to bridge Snail and multiple chromatin “writers”
together. The first evidence came from studies of Peinado and colleagues. They
demonstrated that mouse Snail uses its SNAG domain to associate with HDAC1/2 and
corepressor mSin3A, and recruits the repressor complex to E-cadherin promoter, where
HDAC1/2 deacetylate histone H3 and H4 to create the repressive chromatin environment
147

. Treatment of cells with histone deacetylase inhibitor Trichostatin A (TSA) efficiently

abolished the repressive effect of Snail 147. Based on previously studies demonstrating the
15

connection and mutual communication between histone deacetylation and DNA
methylation

148-151

, they hypothesized that HDACs-mediated histone deacetylation helps

to maintain promoter DNA methylation and gene silencing of E-cadherin. Furthermore,
Peinado and colleagues found that the level of histone H3 lysine 9 dimethylation
(H3K9me2), which is a transcription repression mark, was increased at the E-cadherin
promoter region upon overexpression of Snail in epithelial cells, indicating the
involvement of other repressor complexes containing histone methyltransferase activities
during the regulation process 147.
Herranz and colleagues have recently demonstrated the recruitment of PRC2 by Snail
to E-cadherin promoter, providing a second example for Snail-mediated epigenetic
regulation machinery 152. As mentioned above, PRC2 contains methyltransferase activity
on histone H3 lysine 27, and functions to initiate the transcription silencing process

153

.

Herranz and colleagues found that PRC2 was required for Snail-mediated E-cadherin
suppression, as knockdown of essential PRC2 components Suz12 or Ezh2 abolished the
suppressive effect of Snail in pancreatic cancer cell line RWP-1 as well as colon
adenocarcinoma cell line SW-620

152

. While the interaction between Snail and PRC2

could be either direct or indirect, they demonstrated the necessity of the SNAG domain of
Snail for recruiting PRC2

152

. Other than their studies, researches from two independent

groups showed that the SNAG domain of Snail could interact with both the Ajuba LIM
and PRMT5 proteins, the latter of which then associated with Suz12 (the enzymatic
component of PRC2) through a mediator MEP50 154,155. Based on these results, it seems
likely that the SNAG domain of Snail recruits PRC2 in an Ajuba/PRMT5-dependent
fashion. While still in seek of comprehensive supporting data, Herranz and colleagues
16

suggested another possibility that the interaction of Snail with PRC2 is mediated by
HDACs, according to previous studies showing that HDACs can associate with both
Snail and PRC2, and that histone deacetylation supports PcG-mediated transcription
suppression 156,157.
Together, earlier studies have strongly indicated the crucial role of Snail on
epigenetic silencing of E-cadherin, typically through recruiting multiple repressor
complexes to the E-cadherin promoter region. Recently, we undertook the unbiased
approach of tandem array purification (TAP) coupled with mass spectrometry analysis to
identify chromatin-modifying enzymes that interact with Snail. We found that Snail
interacted with LSD1, a key component of several co-repressor complexes including
CoREST, CtBP and HDAC1/2

33

. As the first identified histone demethylase, LSD1

functions by specifically removing methylation marks on H3K4 and initiating the
transcription repression process

158,159

. Previous studies have established that LSD1 can

cooperate with different transcription factors to selectively repress gene transcription 160163

. Most importantly, LSD1 plays an essential role during development, and

overexpression of LSD1 has been correlated with malignant progression of multiple
cancers, including primary neuroblastic tumors, prostate cancer, and ER-negative breast
cancer 74-77. In our study, we further characterized the functional interaction of Snail with
LSD1 and investigated their roles in mediating chromatin modification during metastasis.
Notably, we suggested a model illustrating that Snail uses its SNAG domain as a
molecular “hook”, or pseudo substrate, to recruit LSD1.
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2-2 Materials and methods
Antibodies and plasmids
Human cDNA for LSD1 and CoREST was amplified from HeLa cDNA and cloned
into pCMV-Tag2B and pcDNA3 with the N-terminal Flag or HA tag, respectively.
Deletion mutants for LSD1 were generated by PCR and subcloned into the GST
expression vector pGEX-6P-3-TEV that contains two protease cleavage sites of tobacco
etch virus. Snail mutants were generated using the QuikChange Mutagenesis kit
(Stratagene, La Jolla, CA) as described previously

164

. All sequences were verified by

DNA sequencing. Antibodies against Snail, LSD1 and CoREST were purchased from
Cell Signaling Technology (Danvers, MA). Anti-Flag and anti-HA antibodies were
obtained from Sigma-Aldrich (St Louis, MO) and Roche Molecular Biochemicals
(Indianapolis, IN), respectively. An antibody against H3K4me2 was purchased from
Millipore (Bedford, MA).
Cell cultures, transfections and reporter assays
The human embryonic kidney HEK293, breast cancer MCF7, MDAMB231 and
SKBR3, prostate cancer PC3 and colon cancer HCT116 cell lines were purchased from
the American Type Culture Collection (Manassas, VA) and grown in Dulbecco’s
modified Eagle’s/F12 medium plus 10% fetal bovine serum as described previously

103

.

Lysine-specific demethylase 1, CoREST and Snail were transiently transfected into cells
using FuGENE 6 (Roche Molecular Biochemicals). For luciferase assay, cells were
plated in six-well plates at a density of 2×105 cells per well. Cells were transfected with
0.3 µg of the pGL3–E-cadherin promoter–luciferase plasmid along with 0.1nM of Snail
18

and/or LSD1 siRNA in each well. To normalize transfection efficiency, cells were also
co-transfected with 0.1 µg of pRL-CMV (Renilla luciferase). At 48 h after transfection,
luciferase activity was measured using the Dual-Luciferase Assay kit (Promega,
Madison, WI). Three independent experiments were performed, and the calculated means
and s.d. values were presented.
GST pull-down assay
Glutathione-S-transferase proteins were expressed as described previously

164

. Cells

were subjected to lysis in GST pull-down buffer (20mM Tris, 150mM NaCl and 1%
Nonidet P-40 with protease cocktail) and rotated with glutathione–Sepharosebound wildtype or deletion mutants of GST–LSD1. The binding complexes were eluted with SDS–
PAGE sample buffer. About one tenth of these elutents were analyzed for the association
of Snail by western blotting and the rest were examined for the presence of purified
GST–LSD1 by Coomassie staining.
Histone demethylation assay
Mononucleosomes were purified from HeLa S3 nuclear extract

165

. The histone

demethylation assay was performed as described previously using mononucleosomes as a
substrate

159,166,167

. Briefly, HEK293 cells were co-transfected with constructs encoding

LSD1, CoREST and Snail. After immunoprecipitation of Snail, complexes were
incubated with mononucleosomes in demethylation buffer (50mM Tris–HCl (pH 8.0),
50mM KCl, 5mM MgCl2, 2mM DTT with proteasome inhibitors) with or without Parnate
or Pargyline at 37ºC for 12 h. Reactions were stopped with SDS sample buffer. Western
blot analysis was performed with an antibody against H3K4me2 (Upstate). The same
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membrane was then stripped and re-probed with α-histone H3 (Abcam, Cambridge, MA,
ab1791) as a substrate-loading control.
Western blot analysis and immunoprecipitation
For protein extraction, 5×105 cells per well were plated onto six-well plates and
transiently transfected with 0.5 mg of pcDNA3-Snail and 0.5 µg of pCMV-Tag2B-LSD1
or vector. At 48 h after transfection, cells were incubated with or without the proteasome
inhibitor MG132 (10 µmol/l) for an additional 6 h before protein extraction and western
blot analysis. Primary antibodies against Flag (M2, 1:1000) and HA (3F10, 1:4000) were
used for protein detection. For immunoprecipitation, HEK293 cells transfected with the
indicated expression plasmids were lysed in buffer (50 mmol/l Tris (pH 7.5), 150 mmol/l
NaCl, 5 mg/ml aprotinin, 1 mg/ml pepstatin, 1% Nonidet P-40, 1 mmol/l EDTA and
0.25% deoxycholate). Total cell lysates (1000 µl) were incubated overnight with 1 mg of
anti-HA or anti-Flag antibody conjugated to agarose beads (Roche Molecular
Biochemicals) at 4ºC. The beads were then washed with lysis buffer, and the
immunoprecipitated protein complexes were resolved by 10% SDS–PAGE.
Invasion assay
Invasion assays were performed as previous described

103

. Briefly, Boyden chambers

were coated with Matrigel according to the manufacturer’s protocol (BD Biosciences,
San Jose, CA). Cancer cells were seeded on top of the Matrigel in the upper chamber, and
the bottom chamber was filled with culture medium containing LPA (10 µM) as the
chemoattractant. Cells that invade through the Matrigel-coated membrane after 4 or 24 h
were fixed with paraformaldehyde, followed by staining with crystal violet. All
20

experiments were conducted at least twice in triplicate. Statistical analysis was performed
with Student’s t-test; a P-value of <0.05 was considered significant.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed according to the protocol
described before

168

with some modifications. The cells were crosslinked with

disuccimidyl glutarate (Pierce, Rockford, IL) and formaldehyde at room temperature.
Cells were subjected to lysis with L1 buffer (50mM Tris, 2mM EDTA, 0.1% IGEPAL,
10% glycerol, 1mM dithiothreitol, 1mM phenylmethylsulfonyl fluoride (PMSF) and
protease inhibitor mixture (pH 8.0)) on ice. After centrifugation, the nuclear pellet was
resuspended in ChIP lysis buffer (1% SDS, 10mM EDTA, 50mM Tris and protease
inhibitor mixture (pH 8.0)). Cell lysates were subjected to sonication and then incubated
with 4 mg of Snail (Abcam) or LSD1 (Sigma-Aldrich) antibody overnight, followed by
incubation with a 50% slurry of protein A–agarose/Salmon sperm DNA (Upstate
Biotechnology, Lake placid, NY) for 3 h at 4ºC. Bound DNA–protein complexes were
eluted and crosslinks were reversed after a series of washes. Purified DNA was
resuspended in TE buffer (10mM Tris–HCl and 1mM EDTA (pH 8.0)) for PCR. Primers
for the E-cadherin promoter were 5’-ACTCCAGGCTAGAGGGTCACC-3’ and 5’CCGCAAGCTCACAGGTGCTTTGCAGTTCC-3’.
Immunofluorescence imaging
For immunofluorescence microscopy, cells were grown on coverslips, fixed with 4%
paraformaldehyde and incubated overnight with anti-LSD1 monoclonal antibody.
Proteins were visualized by incubation with goat anti-mouse conjugated with Alexa Fluor
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568 (Invitrogen, Carlsbad, CA). Finally, coverslips were incubated with 4’, 6’-diamidino2-phenylindole (Sigma-Aldrich) for 20 min and visualized under a fluorescent
microscope.
Immunohistochemical staining
All the breast tumor samples used in this study are invasive ductal carcinoma. The
average age for patients in this group is 56.8 (±13.4) years with either negative (53.3%)
or positive (N1=34.6; N2=12.1%) lymph node metastasis. These samples are of stage I
(12.5%), stage II (38.2%), stage III (41.1%) or stage IV (8.2%). Tissue samples were
stained with anti-Snail (1:200 dilution, Abcam), anti-LSD1 (1:150, Abcam) and antiCoREST (1:150, BD Biosciences) antibodies, and each sample was scored by an H-score
method that combines the values of immunoreaction intensity and the percentage of
tumor cell staining as described previously

103

. Chi-square analysis was used to analyze

the relationship between Snail and LSD1/CoREST expression; statistical significance
was defined as P<0.05.
Subcellular fractionation
Cytoplasmic and nuclear fractions were prepared as described previously 164. Briefly,
cultured cells were suspended in buffer A (10mM HEPES (pH 7.9), 1.5mM MgCl2,
10mM KCl, 0.5mM EDTA and protein inhibitor cocktail) on ice and lysed using a
Dounce homogenizer. The nuclear pellet was washed and isolated. Nuclei were subjected
to lysis in RIPA buffer (150mM NaCl, 1% Nonidet P-40, 0.5% deoxycholate, 0.1% SDS,
50mM Tris (pH 8.0), 25mM NaF, 2mM Na3VO4, 5mM PMSF and 2 µg/ml of aprotinin).
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Poly (ADP-ribose) polymerase and β-tubulin were used as markers of the nuclear and
cytoplasmic fractions, respectively.
Protein model structure
The protein modeling analysis was performed by Dr. Young-In Chi, University of
Kentucky Chandler Medical Center. The three-dimensional (3D) model of the LSD1–
SNAG–Snail complex was built by comparative protein structure modeling using the
program MODELLER 9v3

169

. The input consisted of the template structure and the

alignment of the target sequence with this structure. The output was a 3D model of the
target including all non-hydrogen atoms. This model was derived by minimizing
violations of distance and dihedral angle restraints extracted from the template structure
while maintaining favorable interactions. The template structure was the LSD1–
CoREST–Histone H3 peptide complex structure (Protein Data Bank, 2V1D).
2-3 Results
Snail interacts with LSD1 through the SNAG domain
To identify the potential proteins that interact with Snail, Dr. Peter Zhou generated a
stable HEK293 cell line expressing dual-tagged Snail (Figure 2.1A). After enriching the
nuclear extracts, we carried out a two-step sequential protein purification process with
Flag and hemagglutinin (HA) affinity columns

170

. The final immunocomplexes were

separated on SDS–PAGE and subjected to silver staining (Figure 2.1A). Bound proteins
were excised from the gel and subjected to mass spectrometry analysis. Three known
proteins that interact with Snail, GSK-3β, β-Trcp and PRMT5

123,154

, were found in the

complexes, which validated the specificity of this system. Lysine-specific demethylase 1
23
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, an H3K4 demethylase, was also identified as a protein that associated with Snail. Six

trypsin-digested peptides from a protein with a molecular weight of about 110 kDa were
perfectly matched to the protein sequence of LSD1 (Figure 2.1A).
To validate the physical interaction of Snail with LSD1, we co-expressed Snail–HA
and Flag–LSD1 in HEK293 cells and conducted a co-immunoprecipitation experiment.
After immunoprecipitating LSD1, we detected the associated Snail, and vice versa
(Figure 2.1B), indicating that these two molecules are associated. Interestingly, deletion
of the SNAG (Snail/GFI) domain

93,147,171,172

, a highly conserved repressive domain

present at the N-terminus of several transcription factors (such as Snail and GFI1),
significantly reduced the interaction of Snail with LSD1, indicating that the SNAG
domain is required for this interaction (Figure 2.1B). We also immunoprecipitated
endogenous Snail and LSD1 from PC3, HCT116, MDA-MB 231 and SKBR3 cells and
detected the presence of endogenous LSD1 and Snail, respectively (Figure 2.1C).
Consistent with these data, when GFP–Snail was expressed in HEK293 cells, we found
that Snail was co-localized with endogenous LSD1 in the nucleus (Figure 2.1D). Taken
together, our results indicate that Snail interacts with LSD1 and that the SNAG domain of
Snail is required for mediating their interaction.
The SNAG domain is essential for the stability of Snail
In addition to Snail and GFI1, several other transcription factors, such as Slug,
Scratch, insulinoma-associated protein IA-1 (Insm1) and Ovo-like 1 (OVOL1), also
contain a similar SNAG domain at their N-terminus (Figure 2.2A). This motif is highly
conserved among species and is important for the repressive activity of these
24

transcription factors in mammalian cells

93,147,171,172

. We, along with others, previously

showed that Snail is a highly unstable protein and is regulated by protein stability and
subcellular localization 123,173,174. To test whether the SNAG domain regulates the protein
stability, subcellular localization, and repressive activity of Snail, we generated a Snail
mutant with SNAG domain deletion (ΔSNAG–Snail) and a destabilized d2-GFP with
SNAG domain fused to the N-terminal (SNAG–d2-GFP; Figure 2.2B). Consistent with
previous findings, deletion of the SNAG domain significantly reduced the repressive
activity of Snail on the E-cadherin promoter, whereas adding the SNAG domain to d2GFP had no effect (Figure 2.2B), suggesting that the SNAG domain is required but is not
sufficient for the transcriptional repressive activity of Snail. The failure of ΔSNAG-Snail
to suppress E-cadherin promoter activity was not due to the instability of this molecule,
as treatment with MG132 did not enhance the suppressive function of this mutant (Figure
2.2C). Interestingly, ΔSNAG-Snail became less stable than wild-type Snail, whereas
SNAG-d2-GFP became stabilized in comparison with d2-GFP (Figure 2.2D). To further
extend this finding, we investigated the degradation of these proteins with treatment of
the protein synthesis inhibitor, cycloheximide, for various time intervals. We found that
the protein level of ΔSNAG–Snail significantly decreased after 1 h in comparison with
that of wild-type Snail (Figure 2.2E). In contrast, SNAG–d2-GFP became more stable
than d2-GFP (Figure 2.2F), indicating that the SNAG domain is critical for maintaining
the protein stability of Snail, in addition to its transcriptional repressive function.
We next examined whether the SNAG domain affects the subcellular location of
these proteins. Although the intensity of SNAG–d2-GFP was enhanced because of its
increased stability, d2-GFP and SNAG–d2-GFP were distributed equally in the nucleus
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and cytoplasm (Figure 2.3A). We also expressed wild-type Snail– and ΔSNAG–Snail–
GFP in HEK293 cells and found that both were localized predominantly in the nucleus
(Figure 2.3B). Although ΔSNAG–Snail has significantly decreased protein stability, the
loss of the SNAG domain did not affect its nuclear localization. We also performed
subcellular fractionation analysis and found that the addition or deletion of the SNAG
domain did not change the subcellular localization of d2-GFP or Snail, respectively
(Figure 2.3C). Taken together, our results indicate that the SNAG domain is critical in
controlling the protein stability but not the subcellular location of Snail.

The SNAG domain of Snail interacts with LSD1 by mimicking the structure of the
histone H3 tail

We

also

expressed

d2-GFP

and

SNAG–d2-GFP

in

HEK293

cells.

Immunoprecipitation of SNAG–d2-GFP, but not of d2-GFP, revealed the association of
endogenous LSD1, indicating that the SNAG domain is sufficient for Snail to interact
with LSD1 (Figure 2.4A). Lysine-specific demethylase 1 is a demethylase for H3K4me2
33

. Although it can bind to the histone H3 tail for demethylation, it does not contain a

DNA-binding motif. The manner in which LSD1 binds to a specific promoter chromatin
remains unclear. The X-ray structure of the LSD1–CoREST–Histone H3 peptide
complex has been determined

175,176

, showing that residues of Arg2, Thr6, Arg8, Lys9

and Thr11 of histone H3 (highlighted with blue dots at the top of Figure 2.4B) are critical
for establishing the contact interactions of histone H3 within the catalytic cavity of LSD1.
We noticed that the sequence of the SNAG domain is highly similar to that of the Nterminus of histone H3 and contains arginine- and lysine-rich residues (Figure 2.4B).
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Interestingly, the SNAG domain of Snail contains almost identical residues at four of
these five positions (Arg3, Arg8, Lys9 and Ser11). To identify the critical residues on the
SNAG domain required for interaction with LSD1, we performed alanine scan
mutagenesis on the SNAG domain of Snail (Figure 2.4C). Among the 15 Snail mutants
screened, we found that mutations at Pro2, Arg3, Lys9 and Pro10 decreased the protein
stability of Snail (Figure 2.4C). However, treatment with proteasome inhibitor, MG132,
restored the protein stability of these mutants, indicating that these four residues are
critical for controlling the protein stability of Snail. This is consistent with the finding
that the SNAG domain is important for the protein stability of Snail (Figure 2.2). Similar
to the SNAG deletion mutant of Snail, mutation of these four residues did not alter the
nuclear localization of Snail (Figure 2.4D).
We next examined the interaction of these 15 mutants with LSD1 by
immunoprecipitating endogenous LSD1. We found that Pro2, Arg3, Ser4, Phe5, Arg8
and Lys9 mutants completely lost their ability to interact with LSD1 (Figure 2.4E). The
loss of interaction of these mutants with LSD1 was not due to the instability of these
mutants, as cells were treated with the proteasome inhibitor, MG132, to prevent Snail
from degradation. Consistent with these data, when Snail was immunoprecipitated, the
association of these mutants with LSD1 was also abolished (Figure 2.4E). Interestingly,
mutants that cannot interact with LSD1 also lost their ability to inhibit E-cadherin
promoter luciferase activity, suggesting that the interaction with LSD1 is critical for the
suppressive function of Snail (Figure 2.4F).
We also performed protein modeling analysis on the basis of the structure of the
LSD1–CoREST–Histone H3 complex. We found that the SNAG domain of Snail adopted
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a conformation that was superimposed by the histone H3 tail at the catalytic cavity of
LSD1 (Figure 2.4G). Noticeably, Arg3, Arg8 and Lys9 of the SNAG domain of Snail
participate in similar critical contacts within the catalytic cavity of LSD1, compared with
those of the histone H3 tail. This is consistent with the finding that these mutants lose
their interaction with LSD1 and their suppressive function on the E-cadherin promoter.
As methylation of arginine and lysine residues has been reported on other non-histone
proteins 177, and because Arg3, Arg8 and Lys9 in the SNAG domain of Snail are critical
for the interaction with LSD1, we speculate that methylation of these three residues may
regulate their interaction with LSD1. To test this idea, we immunoprecipitated Snail
protein and performed western blot analysis using antibodies against H3K4, H3K9 and
H3K27 methylation, as well as antibodies against pan-lysine and pan-arginine
methylation. Unfortunately, we were unable to detect the methylation of Snail because of
the lack of a specific methylation antibody on these three residues. Together, our results
indicate that the SNAG domain of Snail interacts with LSD1 by adopting a conformation
similar to that of the N-terminal tail of histone H3.

The amine oxidase domain of LSD1 is responsible for its interaction with Snail

The N-terminal one-third of LSD1 contains a SWIRM (Swi3p, Rsc8p and Moira)
domain that is commonly found in chromatin-remodeling complexes with unknown
functions (Figure 2.5A). The C-terminal two-thirds of LSD1 comprise an amine oxidase
(AO) domain that shares extensive sequence homology with FAD-dependent AO. To
identify the region that is responsible for the LSD1 interaction with Snail, we generated
LSD1 domain-deletion mutants (Figure 2.5A) and co-expressed them with Snail in
28

HEK293 cells. As expected, immunoprecipitation of full-length LSD1 revealed the
association with Snail. A small C-terminal deletion mutant of LSD1 and the AO domain
retained the ability to interact with Snail (lanes 2 and 4; Figure 2.5B). The N-terminal
region of the SWIRM domain, however, was completely incapable of interacting with
Snail (lane 3; Figure 2.5B). In the reciprocal immunoprecipitation experiment,
immunoprecipitation of Snail revealed the associations between full-length and small Cterminal-deleted LSD1 and the AO domain, but not with the SWIRM domain (Figure
2.5C). The input lysates of Figure 2.5B and 2.5C were shown in Figure 2.5D. These
results indicate that the AO domain is required for the interaction of LSD1 with Snail.
Consistent with this result, when wild-type and deletion mutants of glutathione-Stransferase (GST)–LSD1 were pulled down from cell lysates, the SWIRM domain of
LSD1 failed to interact with Snail (lane 3; Figure 2.5E), confirming that the AO domain
but not the SWIRM domain is required for mediating the interaction of LSD1 with Snail.
Although the AO domain of LSD1 shares high sequence homology with other FADcontaining AOs, it contains a unique 100-amino-acid insertion that forms a tower-like
structure (tower domain) protruding away from the AO domain (yellow insertion; Figure
2.5A)

167,175,178,179

. The tower domain divides the AO domain of LSD1 into two

functional lobes, the FAD-binding lobe and the substrate-binding and -recognition lobe.
CoREST binds to the tower domain and allosterically modulates the interaction of the
FAD-binding lobe with the substrate-binding lobe of LSD1 and thus controls the
demethylase activity of LSD1

167,175,178,179

. To further narrow down the region that is

required for the association of the AO domain with Snail, we generated a tower domainonly LSD1 and a tower-deleted AO domain (AOΔTower) by linking FAD- and substrate29

binding lobes with a polyglycine linker as described previously (Figure 2.5A)

179

. When

these deletion mutants were co-expressed with Snail in HEK293 cells, the AO and
AOΔTower mutants were still able to interact with Snail (Figure 2.5F), whereas the tower
domain failed to interact with Snail. Conversely, immunoprecipitation of AO and
AOΔTower, but not of the Tower domain, revealed the association of Snail. These results
indicate that the AO domain, but not the tower region of LSD1, is responsible for the
interaction of LSD1 with Snail.
On the basis of the structural analysis of LSD1, aspartic acid 375 and glutamic acid
379 form a charge interaction with arginine 8 of histone H3, whereas glutamic acids at
positions 553, 555 and 556 interact with arginine 2 of histone H3 (Figure 2.5G). Mutation
of these critical residues within the catalytic domain of LSD1 abolished its catalytic
activity on H3K4 demethylation. Interestingly, mutation of these residues completely
compromised the interaction of LSD1 with Snail (Figure 2.5H). Taken together, our data
indicate that the SNAG domain of Snail adopts a structural conformation similar to that
of the histone H3 tail and interacts with the catalytic domain of LSD1 in a manner similar
to that of histone H3.

CoREST enhances the interaction of LSD1 with Snail and the stability of the
ternary complex

The tower region of LSD1 is required for its interaction with CoREST

167,175,178,179

,a

SANT domain-containing co-repressor. Binding of CoREST not only protects LSD1
from proteasomal degradation in vivo but also modulates the structure of the AO domain
of LSD1 to control the interaction of LSD1 with its substrate, histone H3 159,166. Since the
30

sequence of the SNAG domain is similar to that of the N-terminus of histone H3, and the
SNAG domain of Snail interacts with the AO domain of LSD1, we reasoned that the
association of CoREST with LSD1 may affect the binding and stability of Snail. To test
this idea, we expressed Snail, LSD1 or CoREST in HEK293 cells. Consistent with
previous findings

123,159

, treatment with the proteasome inhibitor MG132 significantly

stabilized Snail and LSD1 (lanes 1 and 2 versus lanes 7 and 8, Figure 2.6A). Coexpression of Snail with wild-type LSD1, ΔTower LSD1 or CoREST did not change the
stability of Snail (lanes 2, 3 and 4, Figure 2.6A). As expected, CoREST enhanced the
stability of wild-type LSD1 but not of ΔTower LSD1 (lane 5 versus lane 6, Figure 2.6A).
Noticeably, expression of Snail, LSD1 and CoREST together significantly enhanced the
protein stability of each in the complex, as much as treatment with proteasome inhibitor
MG132 (lane 5 versus lane 11, Figure 2.6A). These results indicate that the formation of
the Snail–LSD1–CoREST ternary complex is critical for their protein stabilization and
function in vivo. Consistent with this finding, when LSD1 was immunoprecipitated, coexpression of CoREST significantly enhanced the association of LSD1 with Snail (lane 2
versus lane 1, Figure 2.6B; the input lysates were shown in Figure 2.6C). However,
ΔTower LSD1, which does not interact with CoREST, could not enhance the interaction
with Snail in the presence of CoREST (lane 3 versus lane 4, Figure 2.6B). These results
suggest that the binding of CoREST with the tower domain of LSD1 modulated the AO
structure of LSD1, and thus enhanced the interaction of LSD1 with Snail. To further
confirm our finding, we knocked down the expression of endogenous CoREST in
HCT116, PC3 and MDA-MB231 cells, which slightly decreased the levels of
endogenous LSD1 and Snail in these cells (Figure 2.6D). Again, when equal amounts of
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LSD1 were immunoprecipitated (top panel, Figure 2.6E), knockdown of CoREST
expression significantly decreased the interaction of LSD1 with Snail in these cell lines
(Figure 2.6E). As LSD1 resides mainly in the nucleus and Snail is localized in the
nucleus when it is stabilized

123

, we measured the expression of Snail, LSD1 and

CoREST in nuclear extracts from 11 different cancer cell lines. We found that the level of
Snail was highly correlated with the levels of LSD1 and CoREST in these cells (Figure
2.6F). Together, our data indicate that the association of Snail, LSD1 and CoREST is
important for their stability as a functional complex; the binding of CoREST with LSD1
is not only critical for the stability of LSD1 but also modulates the association of LSD1
with Snail.

Interaction with Snail is required for LSD1 recruitment to the E-cadherin promoter
in vivo

We found that the SNAG domain of Snail and the AO domain of LSD1 were required
for their association, and this interaction was regulated by CoREST. Given a high
sequence similarity between the SNAG domain and the N-terminus of histone H3, we
reasoned that Snail used its SNAG domain as a pseudo-substrate for LSD1 by mimicking
the structure of the histone H3 tail, which allowed for the recruitment of LSD1 to its
targeted gene promoter. To test this idea, we immunoprecipitated endogenous LSD1 from
HEK293 (with exogenously expressed Snail), HCT116 and MDA-MB231 cells in the
presence or absence of Parnate (tranylcypromine), a mechanism-based inhibitor that
binds to the catalytic cavity of LSD1 180,181. We found that Parnate significantly disrupted
the interaction of LSD1 with Snail (Figure 2.7A). This inhibitory effect is specific, as
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Parnate did not alter the association of LSD1 with CoREST. A similar finding was also
obtained using another LSD1 inhibitor, Pargyline

182

. To further extend our observation,

we added H3K4me0 (1–21 amino acids), H3K4me2 (1–21 amino acids) and SNAG (1–
17 amino acids) peptides for competition binding during the immunoprecipitation of
endogenous LSD1 in HCT116 and MDA-MB231 cells (Figure 2.7B). We found that H3
peptides significantly disrupted the interaction of LSD1 with Snail. Noticeably, the
SNAG peptide completely abolished the interaction of LSD1 with Snail, suggesting that
the SNAG peptide has higher affinity for binding to LSD1 than does the histone H3
peptide. Together, these results indicate that agents (inhibitors, histone H3 and SNAG
peptides) competing for the binding of the catalytic cavity of LSD1 can disrupt the
association of LSD1 with Snail.
To test whether the Snail complex contains LSD1 demethylase activity, we
immunoprecipitated Snail and incubated the complex with purified mononucleosomes.
We found that the Snail complex was able to demethylate H3K4me2 in vitro and that this
enzymatic activity was suppressed by LSD1 inhibitors Parnate and Pargyline (Figure
2.7C). To further examine whether the Snail–LSD1 complex is associated with the Ecadherin promoter and mediates transcriptional repression during EMT in vivo, we
performed chromatin immunoprecipitation (ChIP) assays on two cancer cell lines. As
expected, Snail and LSD1 can interact with the E-cadherin promoter in these two cell
lines (Figure 2.7D). Interestingly, the interaction of LSD1 with the E-cadherin promoter
was significantly decreased when Snail was specifically knocked down in HCT116 cells
(lane 7 versus lane 8, Figure 2.7E), indicating that the interaction of LSD1 with the Ecadherin promoter is mediated through the association of Snail that binds to the E-box on
33

the E-cadherin promoter through zinc-finger motifs. Consistent with this idea, no H3K4
methylation on the E-cadherin promoter could be detected in HCT116 cells (lane 5,
Figure 2.7E). However, knockdown of Snail or LSD1 expression enhanced the
methylation of H3K4 (lanes 6, 7 and 8, Figure 2.7F). Taken together, our results indicate
that the interaction with LSD1 is critical for the suppressive activity of Snail and that
Snail is required for LSD1 recruitment to the E-cadherin promoter in vivo.

Knockdown of Snail and LSD1 expression suppresses cell migration

To examine the functional relationship of Snail and LSD1 in vivo, we expressed an Ecadherin promoter luciferase construct in MCF7 cells that expresses no detectable
endogenous Snail. As expected, co-expression of Snail suppressed E-cadherin promoter
luciferase activity (Figure 2.8A). However, knockdown of LSD1 expression blocked the
suppressive effect of Snail on the E-cadherin promoter in these cells. We also measured
the cell migration of isogenic MCF7 and Snail/MCF cells (Figure 2.8B). As we have
shown previously, stable expression of Snail in MCF7 cells enhances the migratory
ability of these cells

103

. However, knockdown of LSD1 expression abolished the

enhancement of Snail-mediated cell migration in Snail/MCF7 cells (Figure 2.8B),
whereas knockdown of LSD1 expression in MCF7 cells has no significant effect on cell
migration. These results suggest that the repressive function of Snail depends on LSD1.
Similarly, we knocked down the expression of Snail or LSD1 or CoREST in HCT116,
PC3 and MDA-MB231 cells, which express different levels of endogenous Snail, LSD1
and CoREST, and measured E-cadherin promoter luciferase activity. Knockdown of
CoREST expression partially derepressed suppression of the E-cadherin promoter.
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Knockdown of either Snail or LSD1 expression significantly derepressed the suppression
of the E-cadherin promoter (Figure 2.8C). Knockdown of both Snail and LSD1
expression further enhanced the activity of the E-cadherin promoter luciferase in all three
cell lines tested, suggesting that the functional interaction of Snail and LSD1 is important
for E-cadherin promoter suppression. Consistent with this finding, knockdown expression
of Snail or LSD1 suppressed the migration of HCT116, PC3 and MDA-MB231 cells, and
knockdown of both molecules further enhanced this suppressive effect on migration
(Figure 2.8D). Furthermore, knockdown of Snail, LSD1, CoREST or both Snail and
LSD1 in PC3 and MDA-MB231 cells impaired the invasiveness of these cells (Figure
2.8E). In line with these functional changes, knockdown of either Snail or LSD1
expression decreased the expression of the mesenchymal markers N-cadherin and
vimentin and enhanced the expression of the tight-junction molecule ZO-1 (Figure 2.8F).
Knockdown of both molecules can significantly enhance this effect. We speculate that
this additive effect was due to the higher knockdown efficiency on the functional Snail–
LSD1 repressor complex when both molecules were targeted at the same time. Together,
our results indicate that the functional interaction of Snail with LSD1 is critical in
mediating E-cadherin promoter suppression and enhancing cell migration.

Expression of Snail correlates with the level of LSD1 and CoREST in tumor tissues

Having established that the interaction of Snail and LSD1 is critical for their stability
and for the suppressive function of Snail, we further extended our findings in vivo by
examining the correlation between the expression of Snail and LSD1 in 116 resected
human breast tumor specimens. In agreement with previous findings
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33

, expression of

LSD1 was significantly correlated with the expression of CoREST. Again, consistent
with our results obtained from cell lines, the expression of Snail was highly correlated
with the expression of LSD1 and CoREST in tumor samples (Figure 2.9A and B). These
results in human breast cancer tissues confirm our observations in cell culture, lending
further support to our hypothesis that the interaction of Snail with LSD1 is required for
their stability and for the suppressive function of Snail during cell invasion and
metastasis.
2-4 Discussion
In this study, we showed that the interaction of Snail with LSD1 is critical for their
stability and for the transcriptional repressive function of Snail. Our study provides
several new insights into the regulation of EMT and metastasis. First, Snail may represent
the first unique example of a transcription factor that uses a histone-mimicking motif,
SNAG domain in this case, for recruiting chromatin-modifying enzymes. Although
transcription factors contain DNA-binding motifs, they do not modify chromatin. In
contrast, chromatin-modifying enzymes contain many histone-binding modules (such as
the Bromo, Chromo and PhD domains) and are capable of changing the chromatin
structure through acetylation or methylation, although they lack specific DNA-binding
motifs. The manner in which transcription factors recruit specific chromatin-modifying
enzymes to their target gene promoters remains a subject of major interest and an area of
intensive investigation. We found that the SNAG domain is required and sufficient for
Snail to interact with LSD1. Interestingly, the sequence of the SNAG domain is highly
similar to that of the N-terminus of histone H3 and adopts a conformation similar to that
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of histone H3 at the catalytic cavity of LSD1. Mutation of the critical contact residues
(Arg3, Arg8 and Lys9) of the SNAG domain of Snail completely disrupts the interaction
of Snail with LSD1 and blocks its suppressive activity on the E-cadherin promoter. We
also found that the SNAG domain of Snail interacts with the AO domain of LSD1, which
consists of the catalytic core of LSD1 and is required to interact with the tail of histone
H3 for H3K4 demethylation 167,175,178,179. The interaction of Snail with LSD1 is disrupted
by LSD1 enzymatic inhibitors and histone H3 peptides. In addition, the Snail–LSD1
interaction is regulated by CoREST, which is known to bind to the tower region and
modulates the structure of the AO domain of LSD1 for controlling its interaction with the
histone H3 tail

167,175,178,179

. We showed that expression of CoREST enhanced the

formation of the Snail–LSD1–CoREST ternary complex and significantly stabilized
individual components of the complex, whereas knockdown of CoREST expression
decreased the interaction of LSD1 with Snail. This result is further supported by the
finding that expressions of Snail, LSD1 and CoREST are highly correlated in multiple
cancer cell lines and in the 116 primary breast cancer samples. The region connecting the
SNAG domain and the zinc-fingers in Snail contains a serine-rich motif. We, along with
others, previously showed that this serine-rich motif is highly phosphorylated and
controls the subcellular localization and stability of Snail

123,173,174

. As Snail is a labile

protein, we speculate that deletion or mutation of the SNAG domain disrupts the
interaction of Snail with the LSD1–CoREST complex, and thus leads to the accessibility
of phosphorylation and consequent proteasome degradation by GSK-3β and β-Trcp
123,173,174

. This is supported by the finding that the SNAG domain does not alter

subcellular localization but controls the stability of Snail. Our results also indicate that
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the association of LSD1 with the E-cadherin promoter requires the binding of Snail.
Knockdown of Snail expression inhibits the association of LSD1 with the E-cadherin
promoter. Our results, together with previous findings, lead us to propose a plausible
model for how Snail recruits the LSD1–CoREST complex to its targeted gene promoter
for transcriptional repression (Figure 2.9C). The SNAG domain of Snail resembles a
histone H3-like structure and functions as a molecular ‘hook' (or pseudo-substrate) to
interact with LSD1–CoREST. The formation of this ternary complex stabilizes the
individual components from potential proteasome degradation. Snail brings this complex
to its targeted gene chromatin through the binding of the E-box through zinc-finger
motifs. An overabundant amount of histone H3 at the chromatin region outcompetes the
binding of the SNAG domain with the catalytic core of LSD1 and results in the
demethylation of histone H3K4. Our study is supported by the finding that the SNAG
domain of GFI1 interacts with LSD1 and CoREST and that this interaction is required for
hematopoietic cell differentiation 163. Although our model provides a new mechanism for
the manner in which Snail recruits chromatin-modifying enzymes to target gene
promoters, there are many questions remaining for further investigation. For example,
future studies should address whether Arg3, Arg8 and Lys9 on the SNAG domain are
methylated in vivo and how the SNAG domain is released from the LSD1-binding pocket
after Snail interacts with promoter DNA. Elucidation of these questions will provide new
insights into the regulation of EMT and metastasis.
Second, our study indicates that Snail uses either the SNAG domain or the CtBPbinding motif for recruiting the LSD1–CoREST complex. All vertebrate Snail genes
contain the SNAG domain, but they do not have a CtBP-binding motif. However,
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Drosophila Snail does not contain the SNAG domain, but it has a consensus PxDLSx
motif that is required to interact with the co-repressor CtBP

93,172,183

. Both the SNAG

domain and the CtBP motif are critical for the function of vertebrate and Drosophila
Snail, respectively. Deletion or mutation of the SNAG domain abolishes the repressive
function of SNAG domain-containing transcriptional repressors

184-186

. Similarly,

mutation or deletion of the CtBP-binding motif in Drosophila Snail eliminates its
repressive activity 187. Interestingly, LSD1 was initially identified as a protein associated
with CtBP1 during protein purification and it has been confirmed that the interaction of
LSD1 and CtBP1 is critical for many repressor complexes

170

. Thus, our results suggest

that vertebrate and Drosophila Snail recruit the same LSD1–CoREST co-repressor
complex for their repressive function through either the SNAG domain or the CtBPbinding motif.
Third, our study confirmed that Snail uses different co-repressor complexes to
achieve its repressor function during the EMT process. The reciprocal relationship of
H3K4 and H3K27 methylation in gene regulation is exemplified by the antagonistic
action of TrxG and PcG proteins

188,189

. In our study, Snail interacted with the LSD1–

CoREST complex, resulting in demethylation of H3K4me2 at the E-cadherin promoter to
suppress its expression. Interestingly, Snail has been shown to interact with EZH2 and
Suz12 of PRC2 and induce the trimethylation of H3K27 at the E-cadherin promoter

152

.

The specific mechanism of how the Snail-mediated demethylation of H3K4 and
methylation of H3K27 cooperate to repress E-cadherin requires further investigation. The
findings that Snail also interacts with PRMT5

154

and the Sin3A–HDAC1/2 complex

147

adds another layer of intricacy to the regulation of E-cadherin expression during EMT. In
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Drosophila, transcriptional silencing is initiated through the removal of H3K4
methylation by the LSD1 homologue SU(VAR)3-3

190

, indicating that the demethylation

of H3K4 by LSD1 is the critical initiating step for gene silencing. However, E-cadherin is
frequently silenced through DNA hypermethylation on its promoter in many cancer cell
lines and tumor samples
LSD1–CoREST

191

complex

. The manner in which the demethylation of H3K4 by the
cooperates

with

H3K27

trimethylation

and

H3/H4

deacetylation, and subsequently leads to E-cadherin promoter methylation remains an
important area for further investigation.
In summary, we demonstrated that the interaction with the LSD1–CoREST complex
is critical for the stability and function of Snail. Our results provide a new model for how
a transcription factor recruits chromatin-modifying enzymes to target gene promoter
during transcription. This finding has important clinical ramifications in that chemical
compounds that mimic the structure of the SNAG domain of Snail may hold great
promise for inhibiting the function of Snail in mediating EMT induction and cancer
metastasis.
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Figure 2.1 Snail interacts with LSD1 through the SNAG domain.
(A) The schematic diagram shows the stable expression of dual-tagged Snail in HEK293
cells (top and middle panels). The Snail complex was isolated by two-step
immunopurification, separated on SDS–PAGE and visualized by silver staining. A
protein with molecular weight close to 110 kDa was excised and identified as LSD1 by
mass spectrometry (bottom panel). (B) Flag-tagged LSD1 and HA-tagged wild-type or
SNAG-deleted Snail were co-expressed in HEK293 cells. After immunoprecipitation,
bound Snail or LSD1 was examined by western blotting. (C) Endogenous Snail and
LSD1 were immunoprecipitated from PC3, HCT116, SKBR3 and MDA-MB231 cells
and bound endogenous LSD1 and Snail were examined by western blotting. (D) GFPtagged Snail was expressed in HEK293 cells. After fixation, the cellular localization of
Snail (green) and LSD1 (red) was examined by immunofluorescent staining. Scale bar =
50 µm.

41

Anti-HA
MG132 -

+

Anti-Flag
-

+

MW
(kDa)

IP: LSD1

IP: Snail

250
150

37

HGLINFGIYK
QVNMELAKIK
GIFGSSAVPQPK
VIIIGSGVSGLAAAR
EKDEMVEQEFNR
IADQFLGAMYTLPR

p-Snail
Snail

Input

Snail

Flag-LSD1

LSD1

Flag-LSD1

LSD1

Snail-HA

Snail

Flag-LSD1

LSD1

Snail-HA

Snail

D
GFP
SN (WT)

50

LSD1
Peptides

100
75

Snail-HA

25

42

LSD1

Dapi

Merge

IgG

SKBR3

Snail (WT)
+
Snail (∆SNAG) -

MDA231

HA

PC3

Flag

IgG
+
+
-

HCT116

C

Snail

IgG

B

A

Figure 2.2 The SNAG domain is essential for the stability of Snail.
(A) Sequence alignment of the SNAG domain from several transcriptional repressors.
The consensus sequence is shown in red and the lysine and arginine residues are
highlighted in blue. (B) Scheme showing the SNAG constructs used in this study (top
panel). WT or SNAG-deleted Snail, d2-GFP or SNAG-d2-GFP was co-expressed with
the E-cadherin promoter luciferase construct in MCF7 cells. After 48 h, luciferase
activity was measured by using a Dual-Luciferase Reporter Assay (Promega) (mean ±
s.d. of three separate experiments; bottom panel). (C) Vector, WT- or ΔSNAG-Snail were
co-expressed with the E-cadherin promoter luciferase construct in MCF7 cells. After 42
hr, cells were treated with MG132 for 6 hours and luciferase activity was measured using
the Dual-Luciferase Reporter Assay (Promega) (mean ± SD of three separate
experiments) (bottom panel). (D) WT and SNAG-deleted Snail, d2-GFP and SNAG–d2GFP were expressed in HEK293 cells and analyzed by western blotting. (E) WT or
SNAG-deleted Snail was expressed in HEK293 cells then treated with cycloheximide (10
µg/ml) for different time intervals. The level of Snail was analyzed by western blotting.
Densitometry results from three independent experiments were statistically analyzed and
plotted (bottom panel). A representative western blotting experiment is shown in the top
panel. (F) d2-GFP or SNAG-fused d2-GFP was expressed in HEK293 cells and treated
with cycloheximide as described above. The level of d2-GFP was analyzed by western
blotting. Densitometry results from three independent experiments were statistically
analyzed and plotted (bottom panel) and a representative blot is shown on the top panel.
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Figure 2.3 The SNAG domain does not control the subcellular localization of Snail.
(A) d2-GFP or SNAG-d2-GFP was expressed in HEK293 cells. The subcellular
localization of d2-GFP (green) was visualized by immunofluorescence microscopy (Dapi
for nuclei, red) and assessed in 200 cells at 4 different views. The bar graph shows the
percentages of cells with the indicated subcellular localization. (B) EGFP-tagged WT or
SNAG-deleted Snail was expressed in HEK293 cells. The subcellular localization of
Snail (green) was visualized by immunofluorescence microscopy (Dapi for nuclei, red)
and assessed as described above. (C) d2-GFP or SNAG-d2-GFP and WT or SNAGdeleted Snail was expressed in HeLa cells. The subcellular localization of d2-GFP (top
panel) and Snail (bottom panel) were analyzed by cellular fractionation. Tubulin and
poly-adenosine ribose polymerase (PARP) were used as markers of the cytoplasmic and
nuclear fractions, respectively.
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Figure 2.4 The SNAG domain of Snail interacts with LSD1 by mimicking the structure
of the tail of histone H3.
(A)

d2-GFP

or

SNAG–d2-GFP

was

expressed

in

HEK293

cells.

After

immunoprecipitation of d2-GFP, bound endogenous LSD1 was examined by western
blotting. (B) The schematic diagram shows the sequence alignment of the SNAG domain
with the histone H3 tail. The conserved sequence is highlighted in yellow and arginine
and lysine resides are shown in red. Residues of Arg2, Thr6, Arg8, Lys9 and Thr11 of
histone H3 (highlighted in blue dots on the top) are important for establishing the critical
interaction of histone H3 within the catalytic cavity of LSD1. Triangles at the bottom
represent the residues on the SNAG domain that are important for interacting with LSD1.
(C) Schematic diagram shows the position of the alanine mutations in the SNAG domain
(top panel). The Snail mutants were expressed in HEK293 cells and the level of Snail was
examined by western blotting (bottom panel). (D) EGFP-tagged WT or mutant Snail was
expressed in HEK293 cells and the subcellular localization of Snail (green) was
visualized by immunofluorescence microscopy (DAPI for nuclei, red). Scale bar = 20
µm. (E) WT or mutant Snail was expressed in HEK293 cells treated with MG132 (10
µM) for 6 h. Endogenous LSD1, WT or Snail mutants were immunoprecipitated, and the
bound Snail or endogenous LSD1 was examined by western blotting, respectively. Input
lysates were shown in the bottom panel. (F) Vector, WT or SNAG-domain mutants of
Snail were co-expressed with the E-cadherin promoter luciferase construct in MCF7
cells. After 48 hr, luciferase activity was measured using a Dual-Luciferase Reporter
Assay (Promega) (mean ± SD of three separate experiments). (G) A ball-and-stick model
structure of the LSD1–SNAG–Snail complex (green) superposed to the LSD1–histone
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H3 peptide complex (yellow; PDB access code 2V1d) showing the position of key
interacting residues and the substrate lysine residue (Lys4). The LSD1 molecule is shown
as a partially transparent surface representation.
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Figure 2.5 AO domain of LSD1 is responsible for its interaction with Snail.
(A) The cartoon and schematic diagram shows the structure of LSD1 and the different
deletion constructs used in this study. (B, C) HA-tagged Snail and Flag-tagged full-length
or deletion mutants of LSD1 were co-expressed in HEK293 cells treated with MG132 for
6 h. After immunoprecipitation, bound Snail (B) and LSD1 (C) were examined by
western blotting. (D) Lysates of (B) and (C) were analyzed for the expression of different
deletion mutants of LSD1 and Snail by Western blotting. (E) GST-tagged full-length or
deletion mutants of LSD1 were incubated with lysate from HEK293 cells expressing
Snail. The GST pull-down complex was eluted with SDS–PAGE buffer and about onetenth of these elutents were analyzed for the association of Snail by western blotting
(bottom panel). The rest of the elutents were examined for the presence of purified GST–
LSD1 by Coomassie staining (top panel). (F) Flag-tagged AO domain, AO domain
without Tower (AOΔTower) or Tower domain of LSD1 was co-expressed with Snail in
HEK293 cells treated with MG132 for 6 h. After immunoprecipitation, the bound
deletion mutants of LSD1 and Snail were examined by western blotting. (G) The
schematic diagram shows the positions of D375, E379, D553, D555 and D556 that
interact with the arginine 8 (R8) and arginine 2 (R2) of histone H3, respectively. (H)
Flag-tagged wild-type or mutant LSD1 were co-expressed with HA-tagged Snail in
HEK293 cells. After immunoprecipitation of LSD1 and Snail, the bound Snail and LSD1
were analyzed by Western blotting, respectively.
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Figure 2.6 CoREST enhances the interaction of LSD1 with Snail and the stability of the
ternary complex.

(A) Snail, WT or Tower-deleted LSD1, and CoREST were co-expressed in HEK293
cells. Cells were treated with or without MG132 for 6 h before being collected. The
levels of LSD1, Snail and CoREST were analyzed by western blotting. (B) WT or
Tower-deleted LSD1 and CoREST were co-expressed in Snail/HEK293 cells. After
immunoprecipitation of LSD1, the bound Snail and CoREST were examined by western
blotting. (C) Lysates of (B) were analyzed for the expression of LSD1, CoREST and
Snail by Western blotting. (D) CoREST siRNA or non-target control (NTC) was
expressed in HCT116, PC3 and MDA-MB231 cells. Endogenous LSD1, CoREST and
Snail were examined by western blotting. (E) Cells were prepared as described above in
(D). After endogenous LSD1 was immunoprecipitated, the bound CoREST and Snail
were examined by western blotting. (F) Nuclear extracts from various cancer cell lines
were analyzed for the levels of Snail, LSD1 and CoREST by western blotting. Lamin A
served as the nuclear marker. The expression intensity of these proteins was plotted and
shown (bottom panel).
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Figure 2.7 Interaction with Snail is required for LSD1 recruitment to the E-cadherin
promoter in vivo.
(A) The LSD1 enzymatic inhibitor Parnate (100 µM) was added to the
immunoprecipitation buffer during immunoprecipitation. After endogenous LSD1 was
immunoprecipitated from HEK293 (expressing exogenous Snail), MDA-MB231 and
HCT 116 cells, bound Snail and CoREST were detected by western blotting. (B)
H3K4me0 (1–21 amino acids), H3K4me2 (1–21 amino acids) and SNAG peptides (60
µg/ml) were added to the immunoprecipitation buffer during immunoprecipitation. After
endogenous LSD1 was immunoprecipitated, bound Snail and CoREST were detected by
western blotting as described above. (C) In vitro histone demethylation assay was carried
out as described in the Materials and methods section using mononucleosomes as
substrate. After the reaction, demethylation of histone H3K4 was examined by western
blotting. The statistical analysis for the demethylation from three independent
experiments is shown on the bar graph (top panel). A representative demethylation assay
is shown in the bottom panel. (D) The association of endogenous Snail and LSD1 with
the E-cadherin promoter was analyzed by chromatin immunoprecipitation (ChIP) assay in
HCT116 and BT549 cells. (E) Snail, LSD1 or non-target control (NTC) siRNA was
expressed in HCT116 cells, the association of endogenous Snail and LSD1 with the Ecadherin promoter was analyzed by ChIP assay. (F) Snail, LSD1 or non-target control
siRNA was expressed in HCT116 cells; methylation of H3K4 on the E-cadherin promoter
was analyzed by CHIP assay using anti-H3K4me2 antibody.
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Figure 2.8 Knockdown of Snail and LSD1 expression suppresses cell migration.

(A) An E-cadherin promoter luciferase construct was co-expressed with or without Snail,
non-target control (NTC) or LSD1 siRNA in MCF7 cells. After 48 h, luciferase activities
were normalized and determined (mean ± s.d. of three separate experiments). Luciferase
activities for each sample were statistically analyzed by Student’s t-test (P < 0.01). *, P <
0.001; #, no significance. (B) LSD1 or NTC siRNA was expressed in isogenic MCF7 and
Snail/MCF7 cells. After 48 h, a scratch (‘wound’) was induced in a cell monolayer and
cell culture was continued for an additional 48 h. Images were obtained at the beginning
and at the 48 h time point to monitor the cell migration for the closure of the wound. The
percentage of cell migration was calculated on the basis of the migration of MCF7 cells
(experiments were conducted at least twice in duplicate). Statistical analysis was
performed by Student’s t test (P < 0.01). *, P < 0.001; #, no significance. (C) Snail (SN),
LSD1, CoREST and NTC siRNA were co-expressed with the E-cadherin promoter
luciferase construct in HCT116, PC3 and MDA-MB231 cells. After 48 h, luciferase
activities were normalized and determined. (D) Snail (SN), LSD1 and NTC siRNA were
expressed in HCT116, PC3 and MDA-MB231 cells as described in (C). After 48 h, a
scratch (‘wound’) was induced in a cell monolayer and cell culture was continued for 48
h to measure cell migration as described in (B). The migration of PC3 cells is shown on
the bar graph. (E) The invasive ability of PC3 and MDA-MB231 cells was analyzed by
the invasion assay. Invaded cells from 6 different view areas were counted and plotted as
bar graph (mean ± SEM of three separate experiments). (F) PC3 cells were treated as
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described above and expressions of LSD1, Snail, N-cadherin, vimentin, ZO-1 and Actin
were examined by western blotting.
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E

F
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Figure 2.9 Expression of Snail correlates with the level of LSD1 and CoREST in tumor
tissues.
(A) The 116 surgical specimens of breast cancer were immunostained using antibodies
against Snail, LSD1, CoREST, and the control serum (data not shown). Representative
stainings from the same tumor samples are shown. Scale bar = 100 µm. (B) The
expression patterns of Snail, LSD1 and CoREST in the 116 breast tumor samples were
determined and summarized. Correlation of Snail with LSD1 and CoREST was analyzed
using Fisher’s exact test (P < 0.001). P < 0.05 was set as the criterion for statistical
significance. (C) A proposed model to illustrate how Snail recruits the LSD1-CoREST
complex to the E-cadherin promoter. The SNAG domain of Snail assembles a histone
H3-like structure and serves as a molecular ‘hook’ (or pseudo substrate, a red dot
indicates the critical residues in Snail and histone H3 that interact with LSD1) to interact
with the LSD1–CoRESTcomplex. The formation of this complex stabilizes the individual
components from potential proteasomal degradation. Snail brings this complex to its
targeted gene promoters through the binding of the E-box through the zinc-finger motifs.
An overabundant amount of histone H3 at the chromatin region outcompetes the binding
of the SNAG domain with the catalytic core of LSD1 and results in the demethylation of
histone H3K4.
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Chapter 3: Histone mimics: digging down under
3-1 Introduction
As early as two decades ago, Arents and colleagues identified a common motif shared
by four core histones when they performed crystallographic analysis to determine the
structure of the histone octamer 192. They found that individual polypeptides in the central
portion of histone chains are folded in a similar manner and named this helix-loop-helix
motif the histone fold

192

. Driven by previous findings that a couple of proteins such as

TAFII40 and TAFII60 from Drosophila and macro-H2A from rat also contain histone-like
components, Arents and colleagues reasoned that histone fold might also be prevalent in
certain groups of nonhistone proteins. They performed computer-based motif searches
and sequence analysis, and indeed confirmed the presence of the histone fold in a number
of nonhistone proteins, most of which are involved in protein-protein or protein-DNA
interactions

193

. These proteins, which include transcription factors and enzymes, were

defined to form a distinct histone fold superfamily

194

. Further research by Arents and

colleagues demonstrated that the histone fold plays a role in DNA compaction and
protein dimerization

194

. The histone fold superfamily represents the earliest example of

histones and nonhistone proteins sharing a common motif. It should be noted, however,
that when a certain group of proteins share a common histone-like structure or sequence,
they might appear to have quite different functions. At that time, the biological
significance of “histone mimicking” remains unclear.
Recently, Sampath and colleagues addressed some of these questions by providing a
typical example in the name of G9a, which belongs to the Suv(3-9) family of SET
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domain histone methyltransferases and possesses histone H3 lysine 9 methylation
abilities

195

. Through sequence alignment, they identified a short conserved sequence

within the N-terminal of G9a as well as its family member GLP (G9a-like protein).
Interestingly, they found that the sequence highly resembled the histone H3K9
methylation site. They continued to confirm that G9a was subject to auto-methylation at
lysine 165 within the conserved sequence; and the auto-methylation was required for G9a
to form corepressor complex with HP1γ, the euchromatic isoform of HP1 which was
previously found to recognize methylated lysines at the histone H3 tail through its
prototypical chromodomain. Nuclear magnetic resonance (NMR) spectroscopy analysis
further defined that HP1γ binds methylated G9a with similar manner to that of HP1γmethyl-H3K9.
In our recent study, we demonstrated that the SNAG domain of Snail functions as a
molecular hook, or “pseudo-substrate”, for recruiting LSD1 to E-cadherin promoter for
transcription repression 142. The structural similarity between SNAG domain and histone
H3 tail upon LSD1 binding represents another typical example for histone mimicry.
Baron and colleagues performed a more detailed structural analysis of SNAG-LSD1
binding and found that the positively charged groups and hydroxyl side chains shared by
N-terminal tails of Snail and H3 enable them to fit into the catalytic cavity of LSD1 in a
similar conformation 196. Based on these results, we hypothesized that the SNAG domainmimicking chemical compounds may inhibit Snail-LSD1 association, thus disrupting
their roles in EMT induction and tumor progression. To test this idea, we synthesized a
patch of compounds structurally based on the SNAG domain, and screened candidates
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that may efficiently compete with Snail for LSD1 binding through peptide pulldown
assays.

As mentioned, the Snail-LSD1 interaction provides a unique model of transcription
factor recruiting chromatin enzymes. Since histone H3 peptide has been shown to
associate with multiple chromatin enzymes and modulators by adopting different
conformations

197-201

, we hypothesized that in addition to LSD1, the SNAG domain can

interact with other molecules by mimicking H3 tail and recruit them to its target gene
promoters. In the second part of our study, we tried to address this hypothesis by
applying a SNAG peptide pulldown-mass spectrometry-coupled analysis to identify
SNAG-interacting proteins. Interestingly, among the candidates we identified, many are
chromatin-associated proteins; while some have been previously reported to form
complexes with Snail, a few others have not been published before and may represent
novel targets for studying Snail-mediated epigenetic regulation.

3-2 Materials and methods
Peptide and Chemical compounds
C-terminal biotinylated peptide was synthesized according to the sequence of the
SNAG domain of Snail protein. Chemical compounds were designed based on computer
modeling analysis of the structure of the SNAG domain with various modifications.
Peptide pulldown
Biotin-labeled SNAG peptide was pre-incubated with streptavidin beads. Cell lysate
was then added to the peptide-beads combo for overnight incubation at 4ºC. The complex
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was washed extensively with lysis buffer and PBS and resolved by 10% SDS-PAGE. For
identification of SNAG-associated proteins, the gel was subject to silver staining and the
protein bands were excised for mass spectrometry analysis. For competition assays,
chemicals were added at different concentrations during overnight incubation. Parnate
and DMSO were used as positive and negative control, respectively. After washing and
SDS-PAGE separation steps, western blot was performed using LSD1 antibody.
3-3 Results
Screening of chemical compounds that efficiently disrupt Snail-LSD1 interaction
A batch of 54 compounds was initially entered for the screening process. During the
time of dissertation preparation the screening was still underway. Three chemicals have
been identified so far to significantly inhibit peptide-LSD1 binding at concentration of
100 µM (Figure 3.1). These chemicals were further tested at the concentration of 10 µM
and only one of them retained the inhibitory effect (Figure 3.1). Upon finishing the initial
screening we hope to identify some lead compounds that are effective at the
concentration range of 1-5 µM.
Identification of SNAG-associated proteins
To further identify SNAG-associated proteins besides LSD1, we applied peptide
pulldown-mass spectrometry-coupled analysis as described above. The gel was subject to
silver staining as shown in Figure 3.2. The protein identified include many chromatin
enzymes and modulators, such as LSD1, CoREST, BHC80, HDAC1/2, EZH2, KDM5B
(lysine (K)-specific demethylase 5B, which is an H3K4me3-specific demethylase) and
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NSD2 (Nuclear receptor-binding SET domain protein 2, which harbors histone lysine
methyltransferases activity), among others.
3-4 Discussion
This study is a further extension of our previous research demonstrating that the
SNAG domain of Snail mimics histone H3 tail and functions as a pseudo substrate for
recruiting histone-modifying enzyme LSD1. For the first part, we are screening a pool of
SNAG-mimicking chemical compounds for candidates that can efficiently disrupt SnailLSD1 interaction. Previously, there have been several studies on histone-mimicking
drugs. Chang and colleagues reported that adding a lysine mimic to an established G9a
inhibitor BIX-01294 could enhance its potency in vitro and reduce cell toxicity in vivo
202

. In addition, Nicodeme and colleagues reported that I-BET, a synthetic compound

mimicking acetylated histones, can bind the bromodomain and extra terminal domain
(BET) proteins with high affinity, thus disrupting BET protein-mediated assembly of
chromatin complexes responsible for the expression of key inflammatory genes

203

. In

vivo studies further showed that I-BET treatment conferred protection effect and
suppressed inflammation in mice

203

. While further efforts are still needed for the

development of ideal small molecule inhibitors in specific pathological circumstances,
histone mimicry-based compounds do show great promise. As demonstrated in Chapter
1, Snail and LSD1 cooperate to induce tumor cell migration and invasion, and expression
of Snail highly correlates with that of LSD1 in multiple human breast tumor tissues. In
this regard, SNAG-mimicking chemicals that compete with Snail for LSD1 binding
would hold big potential for inhibiting their roles during metastatic progression of
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tumors.
With the help of Dr. Watt and his colleagues in Department of Biochemistry,
University of Kentucky, we designed a patch of chemicals through computer modeling
based on the structure of SNAG as it fits into the catalytic cavity of LSD1. One of our
considerations during design is the lipid solubility of chemicals which would allow them
to penetrate the lipid cellular membrane to take effect; on the other hand, since a drug is
transported in blood and intracellular fluid, it should be sufficiently water-soluble. The
solubility of a drug is largely determined by its number of hydrogen bond donors vs.
alkyl sidechains. The partition coefficient, which depicts the ratio of compound
concentrations in water/lipid at equilibrium, is used to evaluate solubility. Generally, the
logarithm of the octanol/water partition coefficient, known as Log P, should be in the
range of -0.4 to +5.6. In addition to solubility, the molecular weight of the compounds
was taken into consideration, as it also affects the diffusion rate.
At the starting stage, we are using peptide pulldown-coupled competition assay to
screen these compounds. Experimental conditions such as amount of protein input,
complex incubation time, peptide concentration and washing stringency have been
optimized. We started to test the chemicals at 100 µM and tried to reduce the
concentration without significantly compromising the inhibitory effect on peptide-LSD1
interaction. A couple of “lead compounds” will be determined and further modified for
the improvement of efficacy. A chemical is considered promising candidate if it retains a
significant inhibitory effect within nanomole range, which is comparable to that of LSD1
inhibitor Parnate.
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Once promising candidates have been identified, further assays will be used to test
their biological activities. For example, we plan to perform promoter luciferase assay to
test if chemicals can derepress E-cadherin promoter by disrupting Snail-LSD1 interaction
in different tumor cells; cell invasion and migration assays will also be performed to test
if chemical treatment can compromise these activities of tumor cells. In addition, the
overall cell growth rate upon compound treatment will be measured by MTT assay to
evaluate drug toxicity. Overall, these in vitro screenings will provide molecular basis for
potential in vivo studies in the future to explore the clinical significance of SNAGmimicking compounds.
For the second part of this study, we applied peptide pulldown-mass spectrometrycoupled analysis to identify SNAG-interacting proteins. Our study was inspired by the
“histone code” hypothesis. As stated by Jenuwein and Allis 2, histone tails are subject to
multiple post-translational modifications, which collectively create a “histone code” to be
interpreted by the recruitment of other chromatin modulators through specific recognition
domains. For example, the HAT (histone acetyltransferases) domain has been
demonstrated to mediate histone acetylation, which can be recognized by proteins
harboring bromodomains; the SET domain, by contrast, mediates lysine methylation,
which recruits chromodomain-containing proteins. Other examples include methylated
arginine-recognizing Tudor domain and methylated lysine-recognizing PHD (Plant
Homeo Domain) finger. Due to the structural flexibility, histone tails can adopt various
conformations, which have been illustrated by structural analysis of different chromatin
protein-H3 peptide complexes 197-201. Considering the histone H3 tail-mimicking property
of the SNAG domain, we are wondering if SNAG is also subject to multiple
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modifications and further recognized by different chromatin proteins, which coordinately
control the transcription of Snail target genes. It is possible, for example, that LSD1
works with a yet-to-be-identified lysine methyltransferase to define the methylation status
of the SNAG domain: under specific biological circumstances, one might become tightly
bound to and modify the SNAG domain while the other goes off, or vice versa. It would
be tantalizing to characterize this dynamic “switch”, as well as to specify the other
potential cofactors involved in this regulatory process.
Our enthusiasm was further boosted by recent studies of Sampath and colleagues
demonstrating that the lysine methyltransferase G9a is subject to auto-methylation on its
histone H3-resembling site, and the auto-methylation is required for binding HP1γ to
form a corepressor complex

195

. Their findings offered us several implications. First,

there is an overlap between histone and nonhistone modification systems and one of their
linkages would be the histone-like modification cassettes: the histone mimics. Second,
the histone code hypothesis might go beyond histone and apply more universally to
nonhistone proteins. Third, it might be possible to predict nonhistone targets based on
their structural or sequential similarity to the corresponding histone modification sites.
Indeed, the initial studies performed by Sampath and colleagues, as well as by others,
have identified a number of proteins harboring H3K9-mimicking cassettes and therefore
representing potential targets of G9a. Interestingly, many of these proteins are associated
with chromatin regulation, including mAM 195, which is a murine ATFa-associated factor
and stimulates the activity of histone H3K9 methyltransferase ESET; as well as NSD1
and NSD3

204

, which possess histone H3K36 methyltransferase activities. In this regard,
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extensive sequential and structural analysis will help to predict whether the SNAG
domain is subject to modification by different chromatin enzymes.
Chan and colleagues recently reported an unbiased proteomic screen for histone H3
peptide-bound proteins 205. Through a sensitive pull-down approach in combination with
LC-MS/MS analysis, they identified 86 nuclear proteins that associated with histone H3
peptides harboring different lysine modifications 205. Given the resemblance between the
histone H3 tail and the SNAG domain, a similar strategy to identify interacting proteins
of the SNAG peptide with different modifications would be applicable. Currently,
through a similar approach we identified various proteins interacting with unmodified
SNAG peptide. Excitingly, many of them are chromatin enzymes and modulators. We
also sent a peptide-absent pulldown sample for analysis as the negative control. The
presence of LSD1 and CoREST only in peptide-present pulldown sample confirmed our
findings as depicted in Chapter 1. Furthermore, identification of new SNAG-interacting
candidates goes in line with our hypothesis that SNAG plays a critical role in
coordinating multiple chromatin enzymes and modulators. At this point we cannot
exclude the possibility that these proteins associate with the SNAG peptide through
indirect effects (e.g. through interaction with LSD1). A peptide pulldown assay to
directly capture purified proteins will help to clarify this issue. We are currently
searching literatures on the newly identified candidates and looking to select promising
molecules for the continual study of Snail-mediated epigenetic regulation network.
As conclusion, in this study we are trying to explore our discovery of SNAGmediated LSD1 recruitment by defining SNAG-mimicking compounds for efficient
disruption of Snail-LSD1 interaction, as well as by identifying and characterizing SNAG69

interacting proteins besides LSD1. Our study will contribute methodologically and
theoretically to a better understanding as well as control of Snail-mediated epigenetic
events during cancer development,
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Figure 3.1 Peptide pulldown assay to screen compounds that inhibit SNAG-LSD1
binding.
Chemical compounds were added at concentrations of 100 µM and 10 µM during SNAG
peptide pulldown. The peptide-bound LSD1 was detected by western blot. CT, control
(without chemicals); PAR, Parnate; 1-8, chemical numbers.
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Figure 3.2 Identification of SNAG peptide-interacting proteins.
Peptide pulldown samples were separated on SDS-PAGE and subjected to silver staining
before mass-spectrometry analysis. Peptide-absent sample was used as negative control.
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Chapter 4: Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a
PARP1-dependent manner
4-1 Introduction
Cancer cells distinguish themselves from their normal siblings with the capability of
evading apoptosis and presenting uncontrolled cell division, along with acquiring
malignant characteristics such as invasion and metastasis. The conventional
chemotherapeutic drugs function by introducing DNA damage to impair cell division.
Since most cancer cells outgrow their normal counterparts, the property of rapid DNAreplication makes them more vulnerable to the DNA lesions. On the other side, a portion
of cancer cells have their own defensive strategies, either harboring intrinsic capability to
escape apoptosis or developing resistance following drug exposure, which allow for
tumor recurrence and progression. Chemoresistance is determined by aberrant genetic
settings in combination with diverse epigenetic alterations, reflected by abnormal
signaling pathways controlling drug accumulation and distribution, cell proliferation,
DNA repair and apoptosis

206

. While great effort has been made to elucidate the

underlying mechanism, our knowledge of drug resistance is still fragmentary.
As mentioned, Snail functions not only as a master regulator of epithelialmesenchymal transition (EMT) that promotes tumor metastasis 99,123,171,207,208, but also as
an important molecule that induces immunosuppression, bestows cancer cells with stemlike traits, and mediates cancer cell survival

209

. Typically, Snail can become stabilized

and bind to PTEN promoter to repress its transcription during γ radiation-induced
apoptosis

130

. It has also been documented that upon doxorubicin treatment, the pro75

survival Akt pathway becomes activated to render breast cancer cells resistant to druginduced apoptosis

210

. Based on the findings that PTEN negatively regulates the

PI3K/Akt pathway 211, and that overexpression of Akt can induce NF-κB-dependent Snail
activation

212

, there is a plausible positive feedback loop in which Snail boosts its own

transcription through PTEN suppression. Despite these findings, extra questions remain
in regard to the mechanistic details of Snail-mediated apoptosis protection, and it is not
until we comprehensively understand the “fight-back” mechanism can we develop
efficient strategies to defeat cancer eventually.
We recently applied an affinity purification-mass spectrometry coupled analysis to
identify Snail-interacting proteins, among which are lysine-specific demethylase 1
(LSD1) and poly(ADP-ribose) polymerase 1 (PARP1) 142. In our study, we demonstrated
that Snail uses its SNAG domain as a pseudo-substrate to form complex with LSD1

142

.

Furthermore, we found that the expression of Snail was significantly co-related with that
of LSD1 in multiple human breast cancer tissues

142

. Interestingly, according to other

recent studies, LSD1 can either render tumor cells resistant to DNA damage or reversely
prompt cells to undergo apoptosis in different biological settings, indicating that LSD1
plays a role in cell survival

213-216

. As mentioned, one of the critical oncogenic roles of

Snail lies in apoptosis protection notably through transcriptional repression of PTEN,
which serves as a negative regulator of survival Akt signaling. It would be interesting to
find out if LSD1 is involved in Snail-mediated PTEN suppression and cell survival.
Besides LSD1, PARP1 is another intriguing candidate that serves as a key factor in
DNA repair and cell survival. PARP1 is the founding member of the PARP family
consisting of 18 homologues

217

. PARP1 becomes immediately activated in response to
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single-strand DNA breaks, and utilizes NAD+ as substrate to synthesize poly(ADPribose) polymer (pADPr), which functions as a signal for recruiting other DNA-repairing
enzymes

218,219

. If not repaired, single-strand DNA breaks will cause the replication fork

to stall and double-strand DNA breaks to accumulate during DNA replication
many

breast

cancers

have

defects

in

BRCA1/BRCA2-mediated

220

. Since

homologous

recombination (HR) repair pathway that deals with double-strand breaks, they would rely
on PARP1 to repair DNA lesions. These cancer cells are hypothesized to be highly
sensitive to PARP inhibitors under various cellular stresses. Indeed, PARP inhibitors
have shown more toxicity in cancer cell lines as well as human tumors with
BRCA1/BRCA2 deficiency

221-223

. In addition to DNA repair, PARP1 is actively

involved in transcription regulation, either through directly modulating chromatin
structure or by regulating other chromatin-modifying enzymes and transcription factors
224,225

.

In the current study, we extended our findings by demonstrating that doxorubicin
treatment can enhance Snail-LSD1 interaction in a PARP1-dependent manner. In
addition, Snail contains a potential pADPr-binding motif and is subject to poly(ADPribosyl)ation. Our data also suggested that the enzymatic activity of PARP1 is required
for Snail-LSD1 binding to the PTEN promoter; upon binding, LSD1 demethylates
histone H3 lysine 4 at the promoter region in favor of PTEN transcription suppression
and the downstream Akt phosphorylation. Furthermore, we found that PARP1 inhibitor
AZD2281 can enhance the killing effect of doxorubicin on selective breast and colon
cancer cells. Together, we proposed a new mechanism adopted by cancer cells to defend
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themselves against DNA damage-induced apoptosis, which gives us new implications on
the design of efficient cancer treatment strategies.
4-2 Materials and methods
Plasmids, antibodies and reagents
Human cDNA for PARP1 and LSD1 were amplified from HeLa cDNA and
respectively cloned into pCMV-Tag2B with an N-terminal Flag tag. Snail mutant was
generated using the QuickChange Mutagenesis kit (Stratagene, La Jolla, CA) as
described (Wu et al, 2009a). All sequences were verified by DNA sequencing.
Antibodies against Snail, LSD1, PARP1, PTEN, Akt and Akt-P were purchased from
Cell Signaling Technology (Danvers, MA); anti-H3K4me2 from Millipore (Bedford,
MA); anti-Flag from Sigma-Aldrich (St Louis, MO); anti-HA from Roche Molecular
Biochemicals (Indianapolis, IN); anti-pADPr from Trevigen (Gaithersburg, MD).
Smartpool siRNA against human PARP1 was from Dharmacon. Doxorubicin was
purchased from Sigma-Aldrich, Gallotannin from Santa Cruz, and AZD2281 from
Selleck Chemicals.
Cell cultures and transfections
The human embryonic kidney HEK293, breast cancer MDA-MB157 and colon cancer
HCT116 cell lines were purchased from the American Type Culture Collection
(Manassas, VA) and grown in Dulbecco's modified Eagle's/F12 medium plus 10% fetal
bovine serum as described previously (Wu et al, 2009a). Plasmids were transiently
transfected into cells using FuGENE 6 (Roche Molecular Biochemicals). 48 hours after
transfection, cells were harvested for further experiments.
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Western blot analysis and immunoprecipitation
For protein extraction, 5 × 105 cells per well were plated onto six-well plates, before
protein extraction and western blot analysis. For immunoprecipitation, cells were lysed in
buffer (50 mmol/l Tris (pH 7.5), 150 mmol/l NaCl, 5 μg/ml aprotinin, 1 μg/ml pepstatin,
1% NP-40, 1 mmol/l EDTA and 0.25% deoxycholate). Total cell lysates (1000 μg) were
incubated overnight with desired antibodies conjugated to agarose beads (Roche
Molecular Biochemicals) at 4°C. The beads were then washed 5 times with PBS. The
immunoprecipitated protein complexes were resolved by 10% SDS–PAGE, followed by
western blot analysis.
Chromatin immunoprecipitation
ChIP assays were performed according to the protocol described by Nowak et al
(2005) with some modifications. The cells were crosslinked with disuccimidyl glutarate
(Pierce, Rockford, IL) and formaldehyde at room temperature. Cells were subjected to
lysis with L1 buffer (50 mM Tris, 2 mM EDTA, 0.1% IGEPAL, 10% glycerol, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF) and protease inhibitor
mixture (pH 8.0)) on ice. After centrifugation, the nuclear pellet was resuspended in ChIP
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris and protease inhibitor mixture (pH
8.0)). Cell lysates were subjected to sonication and then incubated with 4 μg of Snail
(Abcam), LSD1 (Sigma-Aldrich) or H3K4me2 antibody overnight, followed by
incubation with a 50% slurry of protein A–agarose/Salmon sperm DNA (Upstate
Biotechnology, Lake placid, NY) for 3 h at 4°C. Bound DNA–protein complexes were
eluted and crosslinks were reversed after a series of washes. Purified DNA was
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resuspended in TE buffer (10 mM Tris–HCl and 1 mM EDTA (pH 8.0)) for PCR. The
primers for the PTEN promoter were 5′-CCGTGCATTTCCCTCTACAC-3′ and 5′GAGGCGAGGATAACGAGCTA-3′.
Real-time quantitative PCR
Quantitative real-time PCR experiments were performed using SYBR Green Power Master
Mix following the manufacturer’s protocol (Applied Biosystems). Experiments were repeated
three times and mean ± s.d. was calculated.

MTT assay
MTT assays were performed using standard protocol. Cell count was optimized. Cells
were incubated with 10 µl MTT reagent for 2 hours before adding 100 µl DMSO reagent.
Absorbance was detected at 570nm. Assays were repeated three times and mean ± s.d.
was calculated.
4-3 Results
PARP1-Snail affinity is enhanced by doxorubicin treatment
Through mass-spectrometry analysis, PARP1, which has a molecular weight of
around 116kDa, was identified besides several already known Snail partners such as
GSK3-β, β-Trcp, PRMT5 and LSD1 (Figure 4.1A). The roles of PARP1 in DNA damage
repair as well as transcription regulation make it a promising candidate for investigating
the mechanism of Snail-mediated PTEN suppression and cell survival. To confirm the
physical interaction of Snail-PARP1, we next performed co-immunoprecipitation
experiments using HEK293 cells over-expressing Snail-HA and Flag-PARP1, as well as
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breast cancer cell line MDA-MB-157 and colon cancer cell line HCT116. As shown in
Figure 4.1B and 4.1C, Snail and PARP1 proteins showed relatively modest interaction in
all of the three cell lines. Interestingly, the protein interaction was significantly enhanced
when the cells were treated with doxorubicin, indicating that upon activation, PARP1
becomes tightly associated with Snail.
PARP1 positively regulates Snail-LSD1 interaction through poly(ADP-ribosyl)ation
of Snail
Since we have recently demonstrated that Snail and LSD1 can form a repressor
complex, we examined if PARP1 can mediate the association of Snail with LSD1. In
HEK293 cells overexpressing Snail and LSD1, doxorubicin treatment significantly
enhanced Snail-LSD1 binding, and similar results could be obtained by co-expressing
PARP1 in the cell (Figure 4.2A). In MDA-MB-157 and HCT116 cells, while doxorubicin
consistently had positive effect, either PARP1 knockdown or treatment of PARP1
inhibitor AZD2281 significantly reduced Snail-LSD1 affinity (Figure 4.2B). These
results indicated that PARP1 promotes the formation of the Snail-LSD1 complex. It
would be interesting to find out the specific mechanism by which PARP1 mediates the
protein interaction.
Through sequence alignment we identified three highly conserved residues Arg151,
Lys152 and Ala153 of Snail protein to be in concert with the corresponding residues of
the previously established pADPr binding motif, in which the positively charged lysine
and arginine are strictly followed by either one of alanine, isoleucine, leucine and valine
(Figure 4.3A). While the sequence surrounding Arg151, Lys152 and Ala153 does not
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exactly follow the rule for the composition of pADPr-binding motif as refined by Gagne
and colleagues, the presence of the most essential residues (Arg151, Lys152) indicates
the potential pADPr docking site on Snail protein. Considering that PARP1 became
activated and tightly bound to Snail upon DNA damage, we went on to investigate
whether Snail can interact with PARP1 through its potential pADPr-binding motif. First
we generated Snail point mutant R151A/K152A and examined its interaction with
PARP1. As shown in Figure 4.3B, the mutant significantly lost PARP1 binding affinity
compared to wild-type Snail, indicating that R151, K152 are critical for PARP1
association. Interestingly, the Snail mutant also significantly lost the binding affinity for
LSD1, further confirming that the presence of PARP1 is required for Snail-LSD1
association (Figure 4.3C). Consistently, when the cells were treated with gallotannin, an
inhibitor of poly(ADP-ribose) glycohydrolase (PARG) which catalyzes the degradation
of pADPr, the association of Snail-LSD1 was significantly enhanced (Figure 4.3D).
Furthermore, the Snail mutant became less stable compared to the wild-type protein
(Figure 4.3E), which was in accord with our previous finding that formation of SnailLSD1 complex was required for maintaining the stability of each component 142.
Upon activation, PARP1 functions by attaching pADPr chain on specific glutamate,
aspartate or lysine residues of its target proteins. To investigate whether Snail can
undergo poly(ADP-ribosyl)ation upon association with PARP1, we immunoprecipitated
Snail protein from the abovementioned stable HEK293 cells, and performed western-blot
using antibody against pADPr. As shown in Figure 4.3F, Snail protein was poly(ADPribosyl)ated, the effect of which could be enhanced by doxorubicin and suppressed by
AZD2281. There was no significant difference in regard to the level of poly(ADP82

ribosyl)ation on wild type and the R151A/K152A mutant Snail (data not shown),
suggesting the existence of multiple modification sites on Snail protein. Together, we
demonstrated that (1) PARP1 positively mediates Snail-LSD1 association as well as their
protein stability through interacting with a potential pADPr-binding motif of Snail; and
(2) Snail protein is subject to PARP1-mediated poly(ADP-ribosyl)ation on multiple
residues.
The enzymatic activity of PARP1 is required for Snail-LSD1 binding to PTEN
promoter
Previous studies have demonstrated that Snail can bind to PTEN promoter to repress
its transcription. The formation of Snail-LSD1-PARP1 complex under DNA damage
condition prompted us to investigate how these proteins potentially cooperate to
downregulate PTEN in favor of cancer cell survival. Since Snail interacts with LSD1
through its SNAG domain, we reasoned that Snail can recruit LSD1 to PTEN promoter
for H3K4 demethylation and gene suppression. We then performed chromatin
immunoprecipitation (ChIP) assays to test this hypothesis. Indeed, both Snail and LSD1
could interact with PTEN promoter in MDA-MB-157 and HCT116 cells (Figure 4.4A).
Interestingly, the binding affinity was significantly increased upon doxorubicin treatment,
indicating that PARP1 becomes activated in response to DNA-damaging agent and
promotes the interaction of Snail/LSD1 with PTEN promoter. Also as expected,
AZD2281 treatment or PARP1 knockdown negatively regulated the complex-promoter
binding. Consistently, the level of H3K4 methylation on PTEN promoter was increased
upon AZD2281 treatment or PARP1 knockdown, and was decreased upon doxorubicin
treatment, further confirming that PAPR1 facilitates the access of LSD1 to PTEN
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promoter (Figure 4.4B). The ChIP samples were also analyzed by quantitative real-time
PCR and similar results were obtained (Figure 4.4C). These results are not only
supported by our earlier data showing that upon poly(ADP-ribosyl)ation of Snail, the
complex becomes stabilized (Figure 4.3E), but also in line with the notion that Snail
works together with corepressors to downregulate PTEN in response to DNA damage, in
such way that Snail fulfils its function as a survival factor.
PARP1 inhibitor AZD2281 enhances the killing effect of doxorubicin on cancer cells
Consistent with the results that doxorubicin enhanced the binding of the Snail-LSD1
repressor complex to PTEN promoter, we found that the protein level of PTEN was
decreased in MDA-MB-157 and HCT116 cells upon doxorubicin treatment (Figure 4.5A,
lane 3). Also as expected, the level of Akt phosphorylation was increased by doxorubicin.
In contrast, AZD2281 treatment had the opposite effect on PTEN expression as well as
Akt phosphorylation (Figure 4.5A, lane 2). Strikingly, when cells were treated with the
two drugs simultaneously, the effect of doxorubicin on PTEN suppression as well as Akt
phosphorylation was compromised by AZD2281 (Figure 4.5A, lane 4). To further test the
idea that cancer cells apply a Snail complex-mediated defensive mechanism to evade
DNA damage-induced apoptosis, we applied doxorubicin in combination with AZD2281
to cancer cells and examined their viability. As seen in Figure 4.5B, either doxorubicin or
AZD2281 treatment can reduce the overall viability of MDA-MB-157 and HCT116 cells;
the number of living cells was further decreased upon treatment of both drugs, indicating
that the drug combination has enhanced cell killing effect. Taken together, our results
suggest that blocking the activity of PARP1 can overcome the effect of doxorubicin on
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PTEN suppression and Akt activation, and sensitize cancer cells to the cytotoxic effect of
doxorubicin.
4-4 Discussion
In this study, we demonstrated that through interacting with and poly(ADPribosyl)ating Snail, PARP1 promotes the formation of Snail-LSD1 repressive complex
and enhances the binding of the complex to PTEN promoter for transcription
suppression. Previously we have shown that Snail uses its highly conserved SNAG
domain as a histone mimicking “hook” to recruit LSD1 to its target gene promoters

142

.

The involvement of PARP1 in this regulation process particularly under the condition of
DNA damage adds another layer to this delicate transcriptional machinery. As the
founding member of the PARP superfamily, PARP1 is a multifunctional protein that not
only plays a role in DNA repair, but also participates in gene transcription regulation. The
effect of PARP1 could either be stimulatory or inhibitory, depending on the specific
environmental context and cellular signals. In the very case discussed here, PAPR1
functions as a co-inhibitor of the Snail-LSD1 complex under DNA damage condition.
Upon activation by doxorubicin, PARP1 uses its pADPr for association with the pADPrbinding motif of Snail, and furthermore promotes the interaction of Snail with LSD1
(Figure 4.2 and 4.3A). Disruption of the pADPr-binding motif by point mutation not only
resulted in loss of Snail-PARP1 association (Figure 4.3B), but also strikingly
compromised Snail-LSD1 complex formation (Figure 4.3C). Consistently, blocking the
degradation of pADPr by inhibiting PARG could enhance Snail-LSD1 interaction (Figure
4.3D). In addition, we found that Snail could undergo poly(ADP-ribosyl)ation on DNA
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damage condition (Figure 4.3F). Based on these results, together with previous finding
that Snail interacts with LSD1 through its SNAG domain, we reasoned that binding and
modification of Snail by PARP1 could change the conformation of Snail and potentially
expose its LSD1-binding motif on the SNAG domain to facilitate Snail-LSD1 interaction.
Therefore, LSD1 can be recruited by Snail to the target gene (PTEN in this case)
promoter, where it demethylates histone H3 lysine 4 in favor of transcription repression
(Figure 4.4 and 4.5A). The model provided here illustrated a tantalizing mechanism of
how cancer cells defense themselves against DNA damage and try to evade PTENmediated apoptosis (Figure 4.6). A detailed computer-based structure analysis would
hopefully further illustrate this dynamic regulatory process and will be done in the near
future. We also tried to explore our findings by specifying the residues on Snail protein
that are subject to poly(ADP-ribosyl)ation. Mutation of the lysine residue on the pADPrbinding motif of Snail did not significantly compromise the level of poly(ADPribosyl)ation, neither did mutations on Lys9, Asp12 or Lys16 of SNAG domain (data not
shown), indicating that Snail can undergo poly(ADP-ribosyl)ation on multiple residues,
which remain to be defined in the future. Together, our study illustrated the cooperation
of Snail, LSD1 and PARP1 in PTEN transcription suppression under DNA damage
condition. Previous to our study, there have been reports demonstrating the dynamic roles
of PARP1 in gene transcription regulation. For example, upon binding to nucleosomes,
PARP1 may regulate the compaction/decompaction of chromatin 226,227; PARP1 may also
exclude histone H1 from its target gene promoters in favor of transcription activation 228.
In addition, PARP1 has been shown to interact noncovalently with DNA
methyltransferase 1 (Dnmt1) and inhibit its enzymatic activity, in such way that it
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regulates genomic methylation patterns

229

. As another typical example, PARP1 can

dissociate Smad complexes from DNA through poly(ADP-ribosyl)ating Smad3 and
Smad4, therefore attenuating Smad-mediated transcription and inhibiting TGF-β-induced
epithelial-mesenchymal transition (EMT)

230

. Since we have demonstrated before the

function of Snail-LSD1 on E-cadherin suppression and EMT induction, there is definite
possibility that PARP1 also participates in this regulation process. In contrast to the
Smad-PARP1 model, however, poly(ADP-ribosyl)ation of Snail by PARP1 would rather
enhance the inhibitory effect of Snail-LSD1 on E-cadherin and promote EMT. We reason
that in different biological settings, cells may rely on different transcriptional machineries
to turn on or off the expression of specific genes in response to various signals, or for the
adaptation of different extracellular and intracellular stresses. Our hypothesis is further
supported by recent finding that PARP1 can poly(ADP-ribosyl)ate and stabilize Snail and
promote Snail-mediated EMT

231

. We speculate that PARP1 regulates Snail-mediated

EMT using a more complicated and delicate mechanism, probably through promoting the
recruitment or release of other histone-modifying enzymes and cofactors (LSD1 for
example) to further modify chromatin. Since both E-cadherin and PTEN loss can
promote the generation of cancer stem cells, another intriguing question is to what extent
the Snail-LSD1-PARP1 complex contributes to cell stemness. While more work is still
needed for clarification of the whole mechanism, our current study provides important
information for the completion of the model of Snail-mediated transcription regulation.
The second insight provided by our study lies in the finding that PARP inhibitors in
conjunction with DNA-damaging agents may represent an effective treatment strategy
against a much wider range of cancers. While the conventional chemotherapeutic drugs
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such as doxorubicin function by targeting DNA synthesis and cell division, unfortunately
they are not smart in pinpointing cancer cells; rather they also do harm to normal cells
with rapid dividing property. Even worse, many solid tumors continually undergoing
chemotherapy will ultimately acquire drug resistance. On the other hand, the targeted
therapy including small molecule inhibitors and monoclonal antibodies may circumvent
the unamiable cytotoxic effects and attack tumor cells with more accuracy and efficiency.
Many cancer cells have defective DNA repair pathways. For example, BRCA1/2
mutations are found in breast and ovarian cancers

232,233

, and mutations of ataxia

telangiectasia mutated (ATM) gene are identified in lymphoid malignancies

234

. In this

regard, targeting DNA repair machineries is a promising strategy for cancer treatments.
Indeed, PARP inhibitors are prevailingly considered as treatment options against
BRCA1/2-deficient tumors due to the synthetic lethality effect

221-223

. Under the same

rationale, PARP1 inhibitors are also used in the treatment of tumors deficient in PTEN,
which plays a critical role in the expression of the repair protein RAD51

235

. Currently,

different PARP inhibitors combined with DNA-damaging agents are under investigation
in several clinical trials

236

. We have shown in our study the enhanced killing effect of

doxorubicin-AZD2281 combination on BRCA1/2 and PTEN intact MDA-MB-157 and
HCT116 cells (Figure 4.5B). Based on our results, we argue that in addition to the
induction of DNA damage, doxorubicin treatment also enhances Snail-LSD1 mediated
PTEN suppression in a PARP1-dependent manner, which results in phosphorylation and
activation of pro-survival Akt. Inhibition of PARP1 can compromise this undesirable
effect while synergizing the DNA-damaging effect of doxorubicin to efficiently kill
cancer cells. While in vivo experiments are required to consolidate our results as well as
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to evaluate the long-term effect of PARP1 inhibition, our data expands potential
therapeutic benefits of PARP1 inhibitors, especially on tumors with high levels of Snail
and LSD1 expression. Furthermore, it is interesting to see if PARP1 inhibitors can
synergize with LSD1 inhibitors and novel SNAG domain-mimicking compounds that
block Snail-LSD1 interaction to treat these kinds of cancers 237.
In summary, we demonstrated that PARP1-mediated poly(ADP-ribosyl)ation of Snail
is critical for Snail-LSD1 complex formation and the downstream PTEN suppression.
Due to the highly heterogeneous and instable nature of cancer cells, as well as the
complexity of the surrounding context, among different cancer cells there is huge
discrepancy in regard to the sensitivity to a specific drug, making it impractical to find a
one-cure-fits-all therapy. The development of efficient treatment strategies would heavily
rely on the understanding of the signaling mechanisms adopted by cancer cells to
overcome the adverse environment for survival. Our study not only provides a new
insight into the working mechanism of the Snail transcriptional machinery, but also
explores the potential application of PARP inhibitors in conjunction with DNA damageinducing agents in targeting cancer cells. As PARP inhibitors are thrust into the limelight
by the encouraging results of early clinical trials, our study would provide extra impetus
for future drug development and help to diversify cancer treatment strategies.

89

Figure 4.1 Doxorubicin enhances PAPR1-Snail interaction.
(A) The Snail complex was isolated from the stable HEK293 cells overexpressing dualtagged Snail (HEK293-SN) by two-step immunopurification. The complex were
separated on SDS–PAGE and visualized by silver staining. LSD1 and PARP1 were
identified by mass spectrometry. (B) Flag-tagged PARP1 and HA-tagged Snail were coexpressed in HEK293 cells. After immunoprecipitation of PARP1, bound Snail was
examined by western blotting. 1 µM of doxorubicin (DOX) was treated 6 hours before
harvesting cells. (C) Endogenous PARP1 was immunoprecipitated from MDA-MB157
and HCT116 cells and bound endogenous Snail was examined by western blotting. The
same doxorubicin treatment condition was used.
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Figure 4.2 PAPR1 positively regulates Snail-LSD1 interaction.
(A) Flag-tagged LSD1 and HA-tagged Snail were co-expressed in HEK293 cells. After
immunoprecipitation of LSD1, bound Snail was examined by western blotting. For
comparison, cells were either co-expressed with Flag-tagged PARP1 (lane 2) or treated
with 1 µM of doxorubicin 6 hours before harvesting cells (lane 3). (B) Endogenous LSD1
was immunoprecipitated from MDA-MB157 and HCT116 cells and bound endogenous
Snail was examined by western blotting. For comparison, cells were treated with
doxorubicin (1 µM for 6 hours, lane 2), AZD2281 (2µM for 24 hours, lane 3), or
transfected with PARP1 siRNA (lane 4).
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Figure 4.3 Snail contains a potential pADPr-binding motif and is subject to poly(ADPribosyl)ation.
(A) Sequence alignment of Snail protein with previously established pADPr-binding
motif. The concert residues were highlighted with red color. (B) Flag-tagged PARP1 was
co-expressed with HA-tagged wild-type or mutant (151 R151A/K152A) Snail in
HEK293 cells. After immunoprecipitation of PARP1, the bound Snail was examined. For
comparison, cells were treated with doxorubicin as indicated. (C) Flag-tagged LSD1 was
co-expressed with HA-tagged wild-type or mutant Snail. After immunoprecipitation of
LSD1, the bound Snail was examined. (D) Flag-tagged LSD1 was co-expressed with
HA-tagged wild-type Snail. After immunoprecipitation of PARP1, the bound Snail was
examined. For comparison, cells were treated with 10 µM of gallotannin (GN) for 6
hours (lane 2). (E) Wild-type or mutant Snail was respectively expressed in HEK293
cells and treated with 10 mg/ml of cycloheximide (CHX) for different time intervals. The
level of Snail was analyzed by western blotting. Densitometry results were statistically
analyzed and plotted (bottom panel, mean ± SD from 3 separate experiments). A
representative western blotting experiment is shown in the top panel. (F) Snail protein
was immunoprecipitated from HKE293-SN, and western blotting was performed using
antibody against pADPr. For comparison, cells were treated with doxorubicin and
AZD2281.
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Figure 4.4 The enzymatic activity of PARP1 is required for Snail-LSD1 binding to
PTEN promoter.
(A) The association of endogenous Snail and LSD1 with the PTEN promoter was
analyzed by chromatin immunoprecipitation (ChIP) assay in MDA-MB157 and HCT116.
For comparison, cells were treated with doxorubicin or AZD2281, or transfected with
PARP1 siRNA. (B) Methylation of H3K4 on the PTEN promoter was analyzed by ChIP
assay using antibody against H3K4me2. For comparison, cells were treated with
doxorubicin or AZD2281, or transfected with PARP1 siRNA. (C) The ChIP samples
were analyzed by quantitative real-time PCR (mean ± SD from three separate
experiments).
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Figure 4.5 AZD2281 enhances the killing effect of doxorubicin on cancer cells.
(A) MDA-MB157 and HCT116 cells were treated with AZD2281, doxorubicin, or these
two drugs together (A/D), and endogenous levels of PTEN, Akt and phosphorylated Akt
(Akt-P) were examined by western blotting. (B) MTT assays were performed using
MDA-MB157 and HCT116 cells and the overall cell viability was determined (mean ±
SD from three separate experiments).
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Figure 4.6 A proposed model illustrating that Snail recruits LSD1 to PTEN promoter in a
PARP1-dependent manner.
Under DNA damage condition, Snail becomes tightly associated with PARP1 and is
subject to PARP1-mediated poly(ADP-ribosyl)ation, which would potentially change the
protein conformation of Snail and promote its association with LSD1. Therefore LSD1
can be recruited by Snail to PTEN promoter for transcription repression. This provides an
alternative mechanism by which PARP1 mediates tumor cell survival.
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Chapter 5: Overall discussion and future plans
Epigenetic deregulation contributes significantly to the development of multiple
human cancers. Accordingly, epigenetic therapy emerges as a novel weapon to fight
against cancer. In particular, there has been growing popularity of chromatin-modifying
enzymes as therapeutic targets, given their nature of diversity and substrate specificity.
While earlier research focused on their function on histones, recent studies have
demonstrated that nonhistone proteins can also become the targets of these enzymes

238-

242

. This adds another layer to the still elusive mechanism governing the epigenetic

regulation process. As the expansion of the list of nonhistone proteins that are subject to
post-translational modifications in a similar pattern to that of histones, a range of critical
questions emerged: What is the determinant, or driving force, for histone-modifying
enzymes to target certain groups of nonhistone proteins? What is the biological
consequence of histones and nonhistone proteins “sharing” specific enzymes? Does the
“histone code” hypothesis also apply to nonhistone proteins? How do the modifications
of nonhistone proteins potentially coordinate with those of histones to regulate gene
transcription under certain biological circumstances? And going further beyond the level
of molecular biology, does this “enzyme sharing” give us any medical implications?
In our study, we demonstrated that the SNAG domain of Snail mimics the histone H3
tail and functions as a “molecular hook” for recruiting LSD1. We further showed that
disruption of Snail and LSD1 interaction can derepress E-cadherin expression and inhibit
EMT induction. Our study provides a novel model revealing the linkage between
transcriptional control and epigenetic regulation, which ideally addresses the above
questions. The histone mimicking strategy has actually been applied by different
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organisms. In a recent study on chromosome segregation dynamics during mitosis, Kelly
and colleagues demonstrated that Thr3 phosphorylation on histone H3, a hallmark of
mitosis, is recognized by the Survivin subunit of the chromosomal passenger complex
(CPC)

243

, which is an essential modulator of chromosome segregation

244

. The H3-

Survivin interaction, based on their results, mediates the recruitment of the CPC to
chromosomes. Jeyaprakash and colleagues further demonstrated that a phospho-mimic Nterminal sequence, which is also found in several mitotic proteins including human
Shugoshin 1, is responsible for Survivin binding

245

. The identification of the epitopes

present in both the histone H3 and several mitotic proteins indicated their mutually
exclusive interactions with the CPC

245

. Together, these studies offer us a clue: histone

mimicry also applies to mitotic-associated proteins and contributes to the fine-tuning of
cell division process. Even in the world of microorganisms, histone mimicry may be
adopted by some pathogens

246

. Given the presence of histone-mimicking proteins based

on genome analysis of multiple viruses, it is possible that these viruses can use similar
strategies to hijack the host epigenetic program. Indeed, Tarakhovsky and colleagues
found that the immunosuppressive NS1 protein of the H3N2 strain of influenza A virus
contains the same sequence as that of human histone H3 tail

247

. They argued that by

mimicking the histone H3 tail, the virus gains access to the host chromatin to target a set
of proteins in the nucleus, therefore impairing the antiviral host cell response.
Considering the far more complicated genomes of mammalians, especially we human
beings, histone mimicry may lurk in much wilder territories than expected. Clarification
of the mechanisms as well as biological functions of histone mimicry will provide
valuable information for the development of small molecule drugs. In the specific case of
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Snail/LSD1-mediated EMT and metastasis, we are currently applying computer modeling
followed by biological screening assays to define SNAG-mimicking compounds that
efficiently disrupt Snail-LSD1 connection. Based on the current progress, we are
confident to identify some promising candidates for further functional testing.
Besides compound screening, we will continue to further investigate Snail-directed
epigenetic regulation that contributes to cancer development. In basal-like breast cancer
(generally referred to as triple-negative breast cancer) that has typical EMT
characteristics and high metastatic potential

248-252

, DNA methylation at the E-cadherin

promoter is not uncommon. What is the driving force for DNMTs to methylate DNA at
the E-cadherin promoter? What are the epigenetic events that happen before the longterm repression by DNA methylation takes effect? How can Snail organize these
epigenetic events into a hierarchic fashion to eventually boost promoter DNA
methylation in specific biological context of EMT? To answer these questions, not only
should we decipher the potential built-in connection between histone modifications and
DNA methylation, we also need to characterize the role of the linker, i.e. Snail, during
this dynamic cellular event. As mentioned, Snail has been shown to associate with
multiple complexes containing distinct histone-modifying activities, such as the
HDAC1/2-containing SIN3 complex, the PRC2 complex with histone H3 lysine 27
trimethylase activity, and the LSD1/CoREST complex. Most recently, studies from our
lab demonstrated that Snail can interact with histone H3 lysine 9 (H3K9)
methyltransferase G9a and is required for the enrichment of G9a and corresponding
H3K9 dimethylation (H3K9me2) at the E-cadherin promoter

253

. The study also showed

that Snail interacted with DNMT1, DNMT3a and DNMT3b in a G9a-dependent manner.
104

Interestingly, H3K9me2 was found to coincide with DNA methylation at the E-cadherin
promoter, and knockdown of G9a expression significantly inhibited DNA methylation at
the promoter region and reactivated E-cadherin expression in MDA-MB-231 breast
cancer cells. The study strongly suggests that Snail-mediated H3K9me2 by G9a is one of
the key events in the maintenance of E-cadherin promoter silencing.
In addition to G9a, our lab found another histone methyltransferase Suv39H1 can
interact with Snail 254. Furthermore, the interaction is mediated by the SNAG domain and
is critical for H3K9 trimethylation (H3K9me3) on the E-cadherin promoter in breast
cancer cells.

It has been demonstrated that Suv39H1-mediated H3K9me3 creates a

docking site for the adaptor molecule HP1, which in turn recruits DNMT3b and HDAC
to respectively catalyze DNA methylation and histone deacetylation

44

. Consistent with

these findings, our lab showed that increased H3K9me3 is accompanied by decreased
acetylation of H3K9 and increased DNA methylation on the E-cadherin promoter, and
knockdown of Suv39H1 can reverse these events and reactivate E-cadherin expression.
Together, the study indicated the critical role of Suv39H1 during Snail-mediated Ecadherin suppression.
The interaction of Snail with G9a and Suv39H1 gave us a couple of implications.
Methylation on H3K9 is a sequential process, with the lysine residue subject to
modifications of up to three methyl groups. While G9a catalyzes the mono- and
dimethylation processes, Suv39H1 uses the product of G9a as substrate, and further
converts it into H3K9me3

255,256

. We reasoned that G9a and Suv39H1 cooperate to

establish the silencing heterochromatin at the E-cadherin promoter, typically with the
help of Snail. Furthermore, there seems to be two distinct routes for H3K9
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methyltransferases to promote DNA methylation at the E-cadherin promoter. In the first
route, G9a directly interacts with DNMTs and recruits them to the E-cadherin promoter
through the association with Snail. In the second route, both G9a and Suv39H1 rely on
their catalytic activities to respectively create H3K9me2 and H3K9me3, with both marks
being able to recruit HP1 and DNMTs to the promoter area

257

. This dual-mode of

regulation may provide a double safety to guarantee the efficient methylation of Ecadherin promoter.
Taken together, it becomes clear that Snail manipulates epigenetic outputs and
masters EMT in a multi-step fashion. First, Snail uses its molecular hook, i.e. the SNAG
domain, to recruit complexes containing LSD1 and HDACs to E-cadherin promoter,
where they create an initial repressive chromatin environment, i.e. H3K4 demethylation
and H3/H4 deacetylation. Previous studies indicated that H3K9me2/3 and H3K4me2/3
are mutually exclusive, due to the fact that H3K9 methyltransferases including G9A and
Suv39H1 fail to bind and methylate H3K4me2/3 substrates

258,259

. We reasoned that

demethylation of H3K4 by LSD1 provides a condition that favors Snail-mediated
association of G9a and Suv39H1 on the E-cadherin promoter. In the meanwhile, HDACs
may mediate the interaction of PRC2 with Snail, therefore promoting PRC2 to land in the
promoter region. Second, G9a associates with the C-terminal region of Snail and is
brought to the promoter region for H3K9me2, while Suv9H1 is drafted by the SNAG
domain to land in the chromatin and uses H3K9me2 as substrate to generate H3K9me3.
Since H3K9 methylation and acetylation are considered mutually exclusive, the level of
acetylation would be further decreased. Third, the recruitment of G9a and Suv39H1
serves as an intermediate step that bridges the initial H3K4 demethylation to the last
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modulation event, as it facilitates promoter DNA methylation by DNMTs. Collectively, a
picture appears in which Snail coordinates multiple epigenetic events to function in great
synergy to suppress E-cadherin and induce EMT (Figure 5.1).
As our knowledge on Snail transcriptional machinery continues growing, there are
still many mechanistic details that remain to be clarified. Firstly, after binding and
bringing enzymes to chromatin, how will the SNAG domain get released to make room
for histones? While we hypothesized that it is overabundant amount of histone proteins at
the chromatin region that outcompetes the binding of the SNAG domain, further
experiments are required to address this issue. Secondly, we are wondering whether the
SNAG domain can be modified by chromatin enzymes such as LSD1 and PARP1 on
specific residues. Development of antibodies specifically recognizing SNAG domain
with different modifications would help to clarify this question. Once specific
modifications on the SNAG domain are identified, we can take one step further to find
out how these modifications may affect the series of epigenetic events leading to EMT.
Alternatively, we can perform paralleled pulldown assays using SNAG peptides with
different modifications, and compare the pulldown proteins with those binding to
unmodified SNAG peptide. The distinct proteins, particularly those with chromatinmodifying activities, that identified from each assay will give us some clues and direct
our future studies. Thirdly, while PRC2-mediated H3K27me3 is associated with gene
repression, its enrichment is unexpectedly anti-correlated with DNA methylation 260,261. It
is hypothesized that the expression of some developmentally important genes is governed
by an “epigenetic switching” reprogramming event. Basically, these genes are repressed
by PRC2 in normal cells, whereas they are subject to hypermethylation in cancer
107

262

.

While the specific mechanism remains unclear, this hypothesis is compatible with our
model that PRC2 recruitment precedes the approaching of DNMTs during cancerous
EMT, and may partially explain the reduced epigenetic plasticity and permanent silencing
of E-cadherin in multiple cancers. Further studies would help to clarify the role of PRC2
in Snail-mediated epigenetic modulation cascade in specific biological settings.
Clarification of Snail-mediated epigenetic regulation will provide molecular basis for
future drug development and help to diversify cancer treatment strategies. Most recently,
Schenk and colleagues applied LSD1 inhibitor tranylcypromine (TCP) in combination
with all-trans retinoic acid (ATRA) therapy to efficiently sensitize acute leukemia of
myeloid (AML) cells to undergo differentiation and decrease their leukemia-initiating
capability in human xenograft models

263

. Consistently, the studies of Harris and

colleagues also indicated the therapeutic potential of LSD1 inhibitors on AML, albeit the
long-term effect of LSD1 inhibitors remains to be evaluated

264

. In addition, inhibitors

targeting histone methyltransferases including G9a are under development and will
potentially enter clinical trials in the coming years

265

. Considering the hierarchic and

interdependent nature of the EMT regulation program, SNAG-mimicking compounds
may efficiently interrupt this epigenetic modulation cascade by competing with Snail for
binding of histone-modifying enzymes such as LSD1, HDACs and Suv39H1, therefore
inhibiting their recruitment by Snail to the E-cadherin promoter. In this regard, these
compounds might work in great synergy with other treatment strategies for the cure of
patients with EMT-related diseases. Extra attention should be paid to evaluate the
pharmacokinetic as well as pharmacodynamic properties of these drugs, especially when
they are combined together to cause potential drug interactions.
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In the third part of our study, we demonstrated that PARP1-mediated poly(ADPribosyl)ation of Snail is required for interaction with LSD1, as well as recruitment of
Snail/LSD1 complex to PTEN promoter. Our study provides a more detailed epigenetic
mechanism of how Snail transcriptionally represses PTEN to mediate tumor survival.
While it remains to be seen if PARP1 is also involved in Snail/LSD1-mediated Ecadherin suppression, our findings added another layer to the delicate Snail
transcriptional machinery and further illustrated Snail as a multi-functional protein
bridging transcriptional control and epigenetic regulation during cancer development.
While further in vivo studies are still pending, our current data indicated that PARP1
inhibitors might be combined with conventional chemo drugs to more efficiently target
cancer cells with high expression of Snail and LSD1.

To conclude, our study has provided new mechanistic details as well as therapeutic
implications of Snail-mediated epigenetic events contributing to cancer development.
Beyond our study, the refreshing Snail story reminds us of the intricacy as well as
integrity of the epigenetic network, and it really prompts me to dig further into the
immense world of epigenetics. With the deluge of modern molecular technology and the
tremendous effort being made while we continue our research, we will eventually be able
to take command over epigenetic deregulation for the great cause of conquering cancer.

109

Figure 5.1 Snail mediates multiple epigenetic events in a hierarchic fashion to suppress
the transcription of E-cadherin .
Through sequential interactions with LSD1/HDAC, PRC2, G9a and Suv39H1, Snail
manages to recruit these repressor machineries to the E-cadherin promoter to modulate
chromatin, and eventually promote DNMT-mediated promoter DNA methylation and
gene silencing.

110

Copyright © Yiwei Lin 2012
111

REFERENCE
1

Waddington, C. H. The Epigenotype. Int J Epidemiol, (2011).

2

Jenuwein, T. & Allis, C. D. Translating the histone code. Science 293, 1074-1080,
(2001).

3

Wang, Y. et al. Beyond the double helix: writing and reading the histone code.
Novartis Found Symp 259, 3-17; discussion 17-21, 163-169 (2004).

4

Turner, B. M. Defining an epigenetic code. Nat Cell Biol 9, 2-6, (2007).

5

Campos, E. I. & Reinberg, D. Histones: Annotating Chromatin. Annual Review of
Genetics 43, 559-599, (2009).

6

Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification:
patterns and paradigms. Nature Reviews Genetics 10, 295-304, (2009).

7

Reik, W. Stability and flexibility of epigenetic gene regulation in mammalian
development. Nature 447, 425-432 (2007).

8

Hotchkiss, R. D. The quantitative separation of purines, pyrimidines, and
nucleosides by paper chromatography. J Biol Chem 175, 315-332 (1948).

9

Ng, H. H. & Bird, A. DNA methylation and chromatin modification. Curr Opin
Genet Dev 9, 158-163, (1999).

10

Bird, A. P. & Wolffe, A. P. Methylation-induced repression--belts, braces, and
chromatin. Cell 99, 451-454, (1999).

11

Ballestar, E. & Wolffe, A. P. Methyl-CpG-binding proteins. Targeting specific
gene repression. Eur J Biochem 268, 1-6, (2001).

12

Goll, M. G. & Bestor, T. H. Eukaryotic cytosine methyltransferases. Annu Rev
Biochem 74, 481-514, (2005).
112

13

Okano, M., Xie, S. & Li, E. Cloning and characterization of a family of novel
mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19, 219-220,
(1998).

14

Okano, M., Bell, D. W., Haber, D. A. & Li, E. DNA methyltransferases Dnmt3a
and Dnmt3b are essential for de novo methylation and mammalian development.
Cell 99, 247-257, (1999).

15

Bestor, T. H. & Ingram, V. M. Two DNA methyltransferases from murine
erythroleukemia cells: purification, sequence specificity, and mode of interaction
with DNA. Proc Natl Acad Sci U S A 80, 5559-5563 (1983).

16

Hermann, A., Goyal, R. & Jeltsch, A. The Dnmt1 DNA-(cytosine-C5)methyltransferase methylates DNA processively with high preference for
hemimethylated target sites. J Biol Chem 279, 48350-48359, (2004).

17

Sancar, A., Lindsey-Boltz, L. A., Unsal-Kacmaz, K. & Linn, S. Molecular
mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu
Rev Biochem 73, 39-85, (2004).

18

Zhu, J. K. Active DNA demethylation mediated by DNA glycosylases. Annu Rev
Genet 43, 143-166, (2009).

19

Popp, C. et al. Genome-wide erasure of DNA methylation in mouse primordial
germ cells is affected by AID deficiency. Nature 463, 1101-1105, (2010).

20

Rai, K. et al. DNA demethylation in zebrafish involves the coupling of a
deaminase, a glycosylase, and gadd45. Cell 135, 1201-1212, (2008).

21

Barreto, G. et al. Gadd45a promotes epigenetic gene activation by repairmediated DNA demethylation. Nature 445, 671-675, (2007).
113

22

Mayer, W., Niveleau, A., Walter, J., Fundele, R. & Haaf, T. Demethylation of the
zygotic paternal genome. Nature 403, 501-502, (2000).

23

Okada, Y., Yamagata, K., Hong, K., Wakayama, T. & Zhang, Y. A role for the
elongator complex in zygotic paternal genome demethylation. Nature 463, 554558, (2010).

24

Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine
in mammalian DNA by MLL partner TET1. Science 324, 930-935, (2009).

25

Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell selfrenewal and inner cell mass specification. Nature 466, 1129-1133, (2010).

26

Bernstein, B. E., Meissner, A. & Lander, E. S. The mammalian epigenome. Cell
128, 669-681, (2007).

27

Downs, J. A., Nussenzweig, M. C. & Nussenzweig, A. Chromatin dynamics and
the preservation of genetic information. Nature 447, 951-958, (2007).

28

Fraser, P. & Bickmore, W. Nuclear organization of the genome and the potential
for gene regulation. Nature 447, 413-417, (2007).

29

Kayne, P. S. et al. Extremely conserved histone H4 N terminus is dispensable for
growth but essential for repressing the silent mating loci in yeast. Cell 55, 27-39,
(1988).

30

Strahl, B. D. & Allis, C. D. The language of covalent histone modifications.
Nature 403, 41-45, (2000).

31

Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705,
(2007).

114

32

Gorisch, S. M., Wachsmuth, M., Toth, K. F., Lichter, P. & Rippe, K. Histone
acetylation increases chromatin accessibility. Journal of Cell Science 118, 58255834, (2005).

33

Shi, Y. Histone lysine demethylases: emerging roles in development, physiology
and disease. Nat Rev Genet 8, 829-833, (2007).

34

Ahn, S. H. et al. Sterile 20 kinase phosphorylates histone H2B at serine 10 during
hydrogen peroxide-induced apoptosis in S. cerevisiae. Cell 120, 25-36, (2005).

35

Fischle, W. et al. Regulation of HP1-chromatin binding by histone H3
methylation and phosphorylation. Nature 438, 1116-1122, (2005).

36

Gelato, K. A. & Fischle, W. Role of histone modifications in defining chromatin
structure and function. Biological Chemistry 389, 353-363, (2008).

37

Marmorstein, R. & Trievel, R. C. Histone modifying enzymes: structures,
mechanisms, and specificities. Biochim Biophys Acta 1789, 58-68, (2009).

38

Lennartsson, A. & Ekwall, K. Histone modification patterns and epigenetic codes.
Biochim Biophys Acta 1790, 863-868, (2009).

39

Suganuma, T. & Workman, J. L. Signals and combinatorial functions of histone
modifications. Annu Rev Biochem 80, 473-499, (2011).

40

Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone
modifications. Cell Res 21, 381-395, (2011).

41

Nelson, C. J., Santos-Rosa, H. & Kouzarides, T. Proline isomerization of histone
H3 regulates lysine methylation and gene expression. Cell 126, 905-916, (2006).

42

Clements, A. et al. Structural basis for histone and phosphohistone binding by the
GCN5 histone acetyltransferase. Mol Cell 12, 461-473, (2003).
115

43

Jin, B., Li, Y. & Robertson, K. D. DNA methylation: superior or subordinate in
the epigenetic hierarchy? Genes Cancer 2, 607-617, (2011).

44

Fuks, F. DNA methylation and histone modifications: teaming up to silence
genes. Curr Opin Genet Dev 15, 490-495, (2005).

45

Suganuma, T. & Workman, J. L. Crosstalk among Histone Modifications. Cell
135, 604-607, (2008).

46

Ooi, S. K. et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de
novo methylation of DNA. Nature 448, 714-717, (2007).

47

Hashimshony, T., Zhang, J., Keshet, I., Bustin, M. & Cedar, H. The role of DNA
methylation in setting up chromatin structure during development. Nature
genetics 34, 187-192, (2003).

48

Lande-Diner, L. et al. Role of DNA methylation in stable gene repression. The
Journal of biological chemistry 282, 12194-12200, (2007).

49

Delaval, K. & Feil, R. Epigenetic regulation of mammalian genomic imprinting.
Curr Opin Genet Dev 14, 188-195, (2004).

50

Heard, E. Delving into the diversity of facultative heterochromatin: the
epigenetics of the inactive X chromosome. Curr Opin Genet Dev 15, 482-489,
(2005).

51

Thorvaldsen, J. L., Verona, R. I. & Bartolomei, M. S. X-tra! X-tra! News from the
mouse X chromosome. Dev Biol 298, 344-353, (2006).

52

Ballas, N. & Mandel, G. The many faces of REST oversee epigenetic
programming of neuronal genes. Curr Opin Neurobiol 15, 500-506, (2005).

116

53

Rai, K. et al. Zebra fish Dnmt1 and Suv39h1 regulate organ-specific terminal
differentiation during development. Mol Cell Biol 26, 7077-7085, (2006).

54

Vire, E. et al. The Polycomb group protein EZH2 directly controls DNA
methylation. Nature 439, 871-874, (2006).

55

Francis, N. J., Saurin, A. J., Shao, Z. & Kingston, R. E. Reconstitution of a
functional core polycomb repressive complex. Mol Cell 8, 545-556, (2001).

56

Cao, R., Tsukada, Y. & Zhang, Y. Role of Bmi-1 and Ring1A in H2A
ubiquitylation and Hox gene silencing. Mol Cell 20, 845-854, (2005).

57

Beisel, C., Imhof, A., Greene, J., Kremmer, E. & Sauer, F. Histone methylation
by the Drosophila epigenetic transcriptional regulator Ash1. Nature 419, 857-862,
(2002).

58

Sanchez-Elsner, T., Gou, D., Kremmer, E. & Sauer, F. Noncoding RNAs of
trithorax response elements recruit Drosophila Ash1 to Ultrabithorax. Science
311, 1118-1123, (2006).

59

Boyer, L. A. et al. Polycomb complexes repress developmental regulators in
murine embryonic stem cells. Nature 441, 349-353, (2006).

60

Lee, T. I. et al. Control of developmental regulators by Polycomb in human
embryonic stem cells. Cell 125, 301-313, (2006).

61

Villeneuve, L. M. & Natarajan, R. The role of epigenetics in the pathology of
diabetic complications. Am J Physiol Renal Physiol 299, F14-25, (2010).

62

Adcock, I. M., Ito, K. & Barnes, P. J. Histone deacetylation: an important
mechanism in inflammatory lung diseases. COPD 2, 445-455 (2005).

117

63

Urdinguio, R. G., Sanchez-Mut, J. V. & Esteller, M. Epigenetic mechanisms in
neurological diseases: genes, syndromes, and therapies. Lancet Neurol 8, 10561072, (2009).

64

Jones, P. A. & Baylin, S. B. The epigenomics of cancer. Cell 128, 683-692,
(2007).

65

Esteller, M. Epigenetics in cancer. N Engl J Med 358, 1148-1159, (2008).

66

Sharma, S., Kelly, T. K. & Jones, P. A. Epigenetics in cancer. Carcinogenesis 31,
27-36, (2010).

67

Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some
human cancers from their normal counterparts. Nature 301, 89-92 (1983).

68

Feinberg, A. P. & Tycko, B. The history of cancer epigenetics. Nat Rev Cancer 4,
143-153, (2004).

69

Shima, K. et al. Prognostic significance of CDKN2A (p16) promoter methylation
and loss of expression in 902 colorectal cancers: Cohort study and literature
review. Int J Cancer 128, 1080-1094, (2011).

70

Feinberg, A. P. & Vogelstein, B. Hypomethylation of ras oncogenes in primary
human cancers. Biochem Biophys Res Commun 111, 47-54, (1983).

71

Rodenhiser, D. & Mann, M. Epigenetics and human disease: translating basic
biology into clinical applications. CMAJ 174, 341-348, (2006).

72

Sawan, C., Vaissiere, T., Murr, R. & Herceg, Z. Epigenetic drivers and genetic
passengers on the road to cancer. Mutat Res 642, 1-13, (2008).

73

Esteller, M. Epigenetics provides a new generation of oncogenes and tumoursuppressor genes. Br J Cancer 94, 179-183, (2006).
118

74

Kahl, P. et al. Androgen receptor coactivators lysine-specific histone demethylase
1 and four and a half LIM domain protein 2 predict risk of prostate cancer
recurrence. Cancer Res 66, 11341-11347, (2006).

75

Schulte, J. H. et al. Lysine-specific demethylase 1 is strongly expressed in poorly
differentiated neuroblastoma: implications for therapy. Cancer Res 69, 20652071, (2009).

76

Metzger, E. et al. LSD1 demethylates repressive histone marks to promote
androgen-receptor-dependent transcription. Nature 437, 436-439 (2005).

77

Lim, S. et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ERnegative breast cancers and a biomarker predicting aggressive biology.
Carcinogenesis 31, 512-520, (2010).

78

Elsasser, S. J., Allis, C. D. & Lewis, P. W. Cancer. New epigenetic drivers of
cancers. Science 331, 1145-1146, (2011).

79

Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently
altered in pancreatic neuroendocrine tumors. Science 331, 1199-1203, (2011).

80

Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease
and prospects for epigenetic therapy. Nature 429, 457-463, (2004).

81

Yoo, C. B. & Jones, P. A. Epigenetic therapy of cancer: past, present and future.
Nat Rev Drug Discov 5, 37-50, (2006).

82

Kelly, T. K., De Carvalho, D. D. & Jones, P. A. Epigenetic modifications as
therapeutic targets. Nat Biotechnol 28, 1069-1078, (2010).

83

Issa, J. P. & Kantarjian, H. Azacitidine. Nat Rev Drug Discov Suppl, S6-7 (2005).

119

84

Fenaux, P. et al. Efficacy of azacitidine compared with that of conventional care
regimens in the treatment of higher-risk myelodysplastic syndromes: a
randomised, open-label, phase III study. Lancet Oncol 10, 223-232, (2009).

85

Yoo, C. B., Cheng, J. C. & Jones, P. A. Zebularine: a new drug for epigenetic
therapy. Biochem Soc Trans 32, 910-912, (2004).

86

Van Rijnsoever, M., Elsaleh, H., Joseph, D., McCaul, K. & Iacopetta, B. CpG
island methylator phenotype is an independent predictor of survival benefit from
5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 9, 2898-2903
(2003).

87

Strathdee, G., MacKean, M. J., Illand, M. & Brown, R. A role for methylation of
the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian
cancer. Oncogene 18, 2335-2341, (1999).

88

Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant
melanoma. Nature 409, 207-211, (2001).

89

Marks, P. A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this
histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25, 84-90,
(2007).

90

Dokmanovic, M., Clarke, C. & Marks, P. A. Histone deacetylase inhibitors:
overview and perspectives. Mol Cancer Res 5, 981-989, (2007).

91

Spannhoff, A., Hauser, A. T., Heinke, R., Sippl, W. & Jung, M. The emerging
therapeutic potential of histone methyltransferase and demethylase inhibitors.
ChemMedChem 4, 1568-1582, (2009).

120

92

Huang, Y., Marton, L. J., Woster, P. M. & Casero, R. A. Polyamine analogues
targeting epigenetic gene regulation. Essays Biochem 46, 95-110, (2009).

93

Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat Rev
Mol Cell Bio 3, 155-166, (2002).

94

Barrallo-Gimeno, A. & Nieto, M. A. The Snail genes as inducers of cell
movement and survival: implications in development and cancer. Development
132, 3151-3161, (2005).

95

Carver, E. A., Jiang, R. L., Lan, Y., Oram, K. F. & Gridley, T. The mouse snail
gene encodes a key regulator of the epithelial-mesenchymal transition. Molecular
and Cellular Biology 21, 8184-8188 (2001).

96

Carver, E. A., Jiang, R., Lan, Y., Oram, K. F. & Gridley, T. The mouse snail gene
encodes a key regulator of the epithelial-mesenchymal transition. Mol Cell Biol
21, 8184-8188, (2001).

97

Thiery, J. P. Epithelial-mesenchymal transitions in development and pathologies.
Curr Opin Cell Biol 15, 740-746, (2003).

98

Kalluri, R. & Weinberg, R. A. The basics of epithelial-mesenchymal transition.
Journal of Clinical Investigation 119, 1420-1428, (2009).

99

Thiery, J. P., Acloque, H., Huang, R. Y. & Nieto, M. A. Epithelial-mesenchymal
transitions in development and disease. Cell 139, 871-890, (2009).

100

Wu, Y. & Zhou, B. P. New insights of epithelial-mesenchymal transition in
cancer metastasis. Acta Bioch Bioph Sin 40, 643-650, (2008).

101

Cardiff, R. D. Epithelial to Mesenchymal Transition Tumors: Fallacious or Snail's
Pace? Clin Cancer Res 11, 8534-8537, (2005).
121

102

Thompson, E. W., Newgreen, D. F. & Tarin, D. Carcinoma invasion and
metastasis: a role for epithelial-mesenchymal transition? Cancer Res 65, 59915995; discussion 5995, (2005).

103

Wu, Y. et al. Stabilization of snail by NF-kappaB is required for inflammationinduced cell migration and invasion. Cancer Cell 15, 416-428, (2009).

104

Christofori, G. New signals from the invasive front. Nature 441, 444-450 (2006).

105

Lopez-Novoa, J. M. & Nieto, M. A. Inflammation and EMT: an alliance towards
organ fibrosis and cancer progression. EMBO Mol Med 1, 303-314, (2009).

106

Wu, Y. & Zhou, B. P. Inflammation: a driving force speeds cancer metastasis.
Cell Cycle 8, 3267-3273, (2009).

107

Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. Tgf-Beta Induced
Transdifferentiation of Mammary Epithelial-Cells to Mesenchymal Cells Involvement of Type-I Receptors. Journal of Cell Biology 127, 2021-2036
(1994).

108

Li, X. X. et al. Intrinsic resistance of tumorigenic breast cancer cells to
chemotherapy. J Natl Cancer I 100, 672-679, (2008).

109

Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell 133, 704-715 (2008).

110

Moody, S. E. et al. The transcriptional repressor Snail promotes mammary tumor
recurrence. Cancer Cell 8, 197-209 (2005).

111

Polyak, K. & Weinberg, R. A. Transitions between epithelial and mesenchymal
states: acquisition of malignant and stem cell traits. Nature Reviews Cancer 9,
265-273, (2009).
122

112

Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev
Cancer 2, 442-454, (2002).

113

Kang, Y. & Massague, J. Epithelial-mesenchymal transitions: twist in
development and metastasis. Cell 118, 277-279, (2004).

114

Cowin, P., Rowlands, T. M. & Hatsell, S. J. Cadherins and catenins in breast
cancer. Curr Opin Cell Biol 17, 499-508, (2005).

115

Thiery, J. P. & Morgan, M. Breast cancer progression with a Twist. Nature
Medicine 10, 777-778, (2004).

116

Yang, J. et al. Twist, a master regulator of morphogenesis, plays an essential role
in tumor metastasis. Cell 117, 927-939 (2004).

117

Bolos, V. et al. The transcription factor Slug represses E-cadherin expression and
induces epithelial to mesenchymal transitions: a comparison with Snail and E47
repressors. J Cell Sci 116, 499-511 (2003).

118

Comijn, J. et al. The two-handed E box binding zinc finger protein SIP1
downregulates E-cadherin and induces invasion. Molecular Cell 7, 1267-1278
(2001).

119

Martin, T. A., Goyal, A., Watkins, G. & Jiang, W. G. Expression of the
transcription factors snail, slug, and twist and their clinical significance in human
breast cancer. Ann Surg Oncol 12, 488-496, (2005).

120

Parker, B. S. et al. Alterations in vascular gene expression in invasive breast
carcinoma. Cancer Research 64, 7857-7866 (2004).

121

Blanco, M. J. et al. Correlation of Snail expression with histological grade and
lymph node status in breast carcinomas. Oncogene 21, 3241-3246, (2002).
123

122

Martin, T. A., Goyal, A., Watkins, G. & Jiang, W. G. Expression of the
transcription factors snail, slug, and twist and their clinical significance in human
breast cancer. Annals of Surgical Oncology 12, 488-496, (2005).

123

Zhou, B. P. et al. Dual regulation of Snail by GSK-3beta-mediated
phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol 6,
931-940, (2004).

124

Zhang, W. et al. Chemoresistance to 5-fluorouracil induces epithelialmesenchymal transition via up-regulation of Snail in MCF7 human breast cancer
cells. Biochem Biophys Res Commun 417, 679-685, (2012).

125

Kaler, P., Galea, V., Augenlicht, L. & Klampfer, L. Tumor associated
macrophages protect colon cancer cells from TRAIL-induced apoptosis through
IL-1beta-dependent stabilization of Snail in tumor cells. PLoS One 5, e11700,
(2010).

126

Zhuo, W. et al. Knockdown of Snail, a novel zinc finger transcription factor, via
RNA

interference

increases

A549

cell

sensitivity

to

cisplatin

via

JNK/mitochondrial pathway. Lung Cancer 62, 8-14, (2008).
127

Zhang, K. et al. Knockdown of snail sensitizes pancreatic cancer cells to
chemotherapeutic agents and irradiation. Int J Mol Sci 11, 4891-4892, (2010).

128

Kurrey, N. K. et al. Snail and slug mediate radioresistance and chemoresistance
by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in
ovarian cancer cells. Stem Cells 27, 2059-2068, (2009).

124

129

Kajita, M., McClinic, K. N. & Wade, P. A. Aberrant expression of the
transcription factors snail and slug alters the response to genotoxic stress.
Molecular and Cellular Biology 24, 7559-7566, (2004).

130

Escriva, M. et al. Repression of PTEN phosphatase by Snail1 transcriptional
factor during gamma radiation-induced apoptosis. Mol Cell Biol 28, 1528-1540,
(2008).

131

Vega, S. et al. Snail blocks the cell cycle and confers resistance to cell death.
Genes Dev 18, 1131-1143, (2004).

132

Roninson, I. B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1):
association with cell senescence and tumour-promoting activities of stromal
fibroblasts. Cancer Lett 179, 1-14, (2002).

133

Gartel, A. L. & Tyner, A. L. The role of the cyclin-dependent kinase inhibitor p21
in apoptosis. Mol Cancer Ther 1, 639-649 (2002).

134

Hotz, B., Visekruna, A., Buhr, H. J. & Hotz, H. G. Beyond epithelial to
mesenchymal transition: a novel role for the transcription factor Snail in
inflammation and wound healing. J Gastrointest Surg 14, 388-397, (2010).

135

Mani, S. A. et al. The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell 133, 704-715, (2008).

136

De Craene, B., van Roy, F. & Berx, G. Unraveling signalling cascades for the
Snail family of transcription factors. Cellular Signalling 17, 535-547, (2005).

137

Yang, Z. B. et al. Pak1 phosphorylation of snail, a master regulator of epithelialto-mesenchyme transition, modulates snail's subcellular localization and
functions. Cancer Research 65, 3179-3184 (2005).
125

138

Gotzmann, J. et al. Hepatocytes convert to a fibroblastoid phenotype through the
cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J Cell Sci 115,
1189-1202 (2002).

139

Peinado, H., Quintanilla, M. & Cano, A. Transforming growth factor beta-1
induces snail transcription factor in epithelial cell lines: mechanisms for epithelial
mesenchymal transitions. J Biol Chem 278, 21113-21123, (2003).

140

Peinado, H. et al. A molecular role for lysyl oxidase-like 2 enzyme in Snail
regulation and tumor progression. Embo Journal 24, 3446-3458, (2005).

141

Barbera, M. J. et al. Regulation of Snail transcription during epithelial to
mesenchymal transition of tumor cells. Oncogene 23, 7345-7354, (2004).

142

Lin, Y. et al. The SNAG domain of Snail1 functions as a molecular hook for
recruiting lysine-specific demethylase 1. EMBO J 29, 1803-1816, (2010).

143

Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads
of development and tumor metastasis. Dev Cell 14, 818-829, (2008).

144

Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nature
Reviews Cancer 2, 442-454, (2002).

145

Weinberg, R. A. Mechanisms of malignant progression. Carcinogenesis 29, 10921095, (2008).

146

Feinberg, A. P. Phenotypic plasticity and the epigenetics of human disease.
Nature 447, 433-440, (2007).

147

Peinado, H., Ballestar, E., Esteller, M. & Cano, A. Snail mediates E-cadherin
repression

by

the

recruitment

of

the

Sin3A/histone

(HDAC1)/HDAC2 complex. Mol Cell Biol 24, 306-319 (2004).
126

deacetylase

1

148

Mutskov, V. J., Farrell, C. M., Wade, P. A., Wolffe, A. P. & Felsenfeld, G. The
barrier function of an insulator couples high histone acetylation levels with
specific protection of promoter DNA from methylation. Genes Dev 16, 15401554, (2002).

149

Ou, J. N. et al. Histone deacetylase inhibitor Trichostatin A induces global and
gene-specific DNA demethylation in human cancer cell lines. Biochem
Pharmacol 73, 1297-1307, (2007).

150

Spurling, C. C. et al. The short chain fatty acid butyrate induces promoter
demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer
60, 692-702, (2008).

151

Smith, K. M. et al. H2B- and H3-specific histone deacetylases are required for
DNA methylation in Neurospora crassa. Genetics 186, 1207-1216, (2010).

152

Herranz, N. et al. Polycomb complex 2 is required for E-cadherin repression by
the snail1 transcription factor. Molecular and Cellular Biology 28, 4772-4781,
(2008).

153

Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H. & Helin, K. Genome-wide
mapping of Polycomb target genes unravels their roles in cell fate transitions.
Genes Dev 20, 1123-1136, (2006).

154

Hou, Z. et al. The LIM protein AJUBA recruits protein arginine methyltransferase
5 to mediate SNAIL-dependent transcriptional repression. Mol Cell Biol 28, 31983207, (2008).

155

Langer, E. M. et al. Ajuba LIM proteins are snail/slug corepressors required for
neural crest development in Xenopus. Dev Cell 14, 424-436, (2008).
127

156

Poux, S., Melfi, R. & Pirrotta, V. Establishment of Polycomb silencing requires a
transient interaction between PC and ESC. Genes Dev 15, 2509-2514, (2001).

157

van der Vlag, J. & Otte, A. P. Transcriptional repression mediated by the human
polycomb-group protein EED involves histone deacetylation. Nat Genet 23, 474478, (1999).

158

Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase
homolog LSD1. Cell 119, 941-953 (2004).

159

Shi, Y. J. et al. Regulation of LSD1 histone demethylase activity by its associated
factors. Mol Cell 19, 857-864, (2005).

160

Amente, S. et al. LSD1-mediated demethylation of histone H3 lysine 4 triggers
Myc-induced transcription. Oncogene 29, 3691-3702, (2010).

161

Su, S. T. et al. Involvement of histone demethylase LSD1 in Blimp-1-mediated
gene repression during plasma cell differentiation. Mol Cell Biol 29, 1421-1431,
(2009).

162

Tsai, W. W., Nguyen, T. T., Shi, Y. & Barton, M. C. p53-targeted LSD1
functions in repression of chromatin structure and transcription in vivo. Mol Cell
Biol 28, 5139-5146, (2008).

163

Saleque, S., Kim, J., Rooke, H. M. & Orkin, S. H. Epigenetic regulation of
hematopoietic differentiation by Gfi-1 and Gfi-1b is mediated by the cofactors
CoREST and LSD1. Mol Cell 27, 562-572 (2007).

164

Wu, Y., Evers, B. M. & Zhou, B. P. Small C-terminal domain phosphatase
enhances snail activity through dephosphorylation. J Biol Chem 284, 640-648,
(2009).
128

165

Utley, R. T. et al. In vitro analysis of transcription factor binding to nucleosomes
and nucleosome disruption/displacement. Methods Enzymol 274, 276-291 (1996).

166

Lee, M. G., Wynder, C., Cooch, N. & Shiekhattar, R. An essential role for
CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437, 432-435,
(2005).

167

Yang, M. et al. Structural basis for CoREST-dependent demethylation of
nucleosomes by the human LSD1 histone demethylase. Mol Cell 23, 377-387,
(2006).

168

Nowak, D. E., Tian, B. & Brasier, A. R. Two-step cross-linking method for
identification of NF-kappaB gene network by chromatin immunoprecipitation.
Biotechniques 39, 715-725, (2005).

169

Eswar, N. et al. Comparative protein structure modeling using Modeller. Curr
Protoc Bioinformatics Chapter 5, Unit 5 6, (2006).

170

Shi, Y. et al. Coordinated histone modifications mediated by a CtBP co-repressor
complex. Nature 422, 735-738, (2003).

171

Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene
expression in epithelial tumour cells. Nat Cell Biol 2, 84-89, (2000).

172

Barrallo-Gimeno, A. & Nieto, M. A. Evolutionary history of the Snail/Scratch
superfamily. Trends Genet 25, 248-252, (2009).

173

Dominguez, D. et al. Phosphorylation regulates the subcellular location and
activity of the snail transcriptional repressor. Mol Cell Biol 23, 5078-5089 (2003).

129

174

Yook, J. I., Li, X. Y., Ota, I., Fearon, E. R. & Weiss, S. J. Wnt-dependent
regulation of the E-cadherin repressor snail. J Biol Chem 280, 11740-11748,
(2005).

175

Forneris, F., Binda, C., Adamo, A., Battaglioli, E. & Mattevi, A. Structural basis
of LSD1-CoREST selectivity in histone H3 recognition. J Biol Chem 282, 2007020074, (2007).

176

Forneris, F., Binda, C., Battaglioli, E. & Mattevi, A. LSD1: oxidative chemistry
for multifaceted functions in chromatin regulation. Trends Biochem Sci 33, 181189, (2008).

177

Huang, J. & Berger, S. L. The emerging field of dynamic lysine methylation of
non-histone proteins. Curr Opin Genet Dev 18, 152-158, (2008).

178

Stavropoulos, P., Blobel, G. & Hoelz, A. Crystal structure and mechanism of
human lysine-specific demethylase-1. Nat Struct Mol Biol 13, 626-632, (2006).

179

Chen, Y. et al. Crystal structure of human histone lysine-specific demethylase 1
(LSD1). Proc Natl Acad Sci U S A 103, 13956-13961, (2006).

180

Schmidt, D. M. & McCafferty, D. G. trans-2-Phenylcyclopropylamine is a
mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 46,
4408-4416, (2007).

181

Yang, M. et al. Structural basis for the inhibition of the LSD1 histone
demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry
46, 8058-8065, (2007).

182

Yang, M. et al. Structural basis of histone demethylation by LSD1 revealed by
suicide inactivation. Nat Struct Mol Biol 14, 535-539, (2007).
130

183

Chinnadurai, G. CtBP, an unconventional transcriptional corepressor in
development and oncogenesis. Mol Cell 9, 213-224, (2002).

184

Okubo, T. et al. Down-regulation of promoter 1.3 activity of the human aromatase
gene in breast tissue by zinc-finger protein, snail (SnaH). Cancer Res 61, 13381346 (2001).

185

Zhu, J. et al. Growth factor independent-1 induced by IL-4 regulates Th2 cell
proliferation. Immunity 16, 733-744, (2002).

186

Fiolka, K. et al. Gfi1 and Gfi1b act equivalently in haematopoiesis, but have
distinct, non-overlapping functions in inner ear development. EMBO Rep 7, 326333, (2006).

187

Hemavathy, K., Hu, X., Ashraf, S. I., Small, S. J. & Ip, Y. T. The repressor
function of snail is required for Drosophila gastrulation and is not replaceable by
Escargot or Worniu. Dev Biol 269, 411-420, (2004).

188

Sparmann, A. & van Lohuizen, M. Polycomb silencers control cell fate,
development and cancer. Nat Rev Cancer 6, 846-856, (2006).

189

Schuettengruber, B., Chourrout, D., Vervoort, M., Leblanc, B. & Cavalli, G.
Genome regulation by polycomb and trithorax proteins. Cell 128, 735-745,
(2007).

190

Rudolph, T. et al. Heterochromatin formation in Drosophila is initiated through
active removal of H3K4 methylation by the LSD1 homolog SU(VAR)3-3. Mol
Cell 26, 103-115, (2007).

131

191

Lombaerts, M. et al. E-cadherin transcriptional downregulation by promoter
methylation but not mutation is related to epithelial-to-mesenchymal transition in
breast cancer cell lines. Br J Cancer 94, 661-671, (2006).

192

Arents, G., Burlingame, R. W., Wang, B. C., Love, W. E. & Moudrianakis, E. N.
The nucleosomal core histone octamer at 3.1 A resolution: a tripartite protein
assembly and a left-handed superhelix. Proc Natl Acad Sci U S A 88, 1014810152 (1991).

193

Baxevanis, A. D., Arents, G., Moudrianakis, E. N. & Landsman, D. A variety of
DNA-binding and multimeric proteins contain the histone fold motif. Nucleic
Acids Res 23, 2685-2691, (1995).

194

Arents, G. & Moudrianakis, E. N. The histone fold: a ubiquitous architectural
motif utilized in DNA compaction and protein dimerization. Proc Natl Acad Sci
U S A 92, 11170-11174 (1995).

195

Sampath, S. C. et al. Methylation of a histone mimic within the histone
methyltransferase G9a regulates protein complex assembly. Mol Cell 27, 596-608,
(2007).

196

Baron, R., Binda, C., Tortorici, M., McCammon, J. A. & Mattevi, A. Molecular
mimicry and ligand recognition in binding and catalysis by the histone
demethylase LSD1-CoREST complex. Structure 19, 212-220, (2011).

197

Ruthenburg, A. J. et al. Histone H3 recognition and presentation by the WDR5
module of the MLL1 complex. Nat Struct Mol Biol 13, 704-712, (2006).

198

Lan, F. et al. Recognition of unmethylated histone H3 lysine 4 links BHC80 to
LSD1-mediated gene repression. Nature 448, 718-722, (2007).
132

199

Huang, Y., Fang, J., Bedford, M. T., Zhang, Y. & Xu, R. M. Recognition of
histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science
312, 748-751, (2006).

200

Xiao, B. et al. Structure and catalytic mechanism of the human histone
methyltransferase SET7/9. Nature 421, 652-656, (2003).

201

Li, H. et al. Molecular basis for site-specific read-out of histone H3K4me3 by the
BPTF PHD finger of NURF. Nature 442, 91-95, (2006).

202

Chang, Y. et al. Adding a lysine mimic in the design of potent inhibitors of
histone lysine methyltransferases. J Mol Biol 400, 1-7, (2010).

203

Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic.
Nature 468, 1119-1123, (2010).

204

Henkels, C. H. & Khorasanizadeh, S. Implications of a histone code mimic in
epigenetic signaling. Mol Cell 27, 521-522, (2007).

205

Chan, D. W. et al. Unbiased proteomic screen for binding proteins to modified
lysines on histone H3. Proteomics 9, 2343-2354, (2009).

206

Roberti, A., La Sala, D. & Cinti, C. Multiple genetic and epigenetic interacting
mechanisms contribute to clonally selection of drug-resistant tumors: current
views and new therapeutic prospective. J Cell Physiol 207, 571-581, (2006).

207

Cano, A. et al. The transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83, (2000).

208

Savagner, P. Leaving the neighborhood: molecular mechanisms involved during
epithelial-mesenchymal transition. Bioessays 23, 912-923, (2001).

209

Wu, Y. & Zhou, B. P. Snail: More than EMT. Cell Adh Migr 4, 199-203, (2010).
133

210

Li, X., Lu, Y., Liang, K., Liu, B. & Fan, Z. Differential responses to doxorubicininduced phosphorylation and activation of Akt in human breast cancer cells.
Breast Cancer Res 7, R589-597, (2005).

211

Yamada, K. M. & Araki, M. Tumor suppressor PTEN: modulator of cell
signaling, growth, migration and apoptosis. J Cell Sci 114, 2375-2382 (2001).

212

Julien, S. et al. Activation of NF-kappaB by Akt upregulates Snail expression and
induces epithelium mesenchyme transition. Oncogene 26, 7445-7456, (2007).

213

Jie, Z. et al. Trans-2-phenylcyclopropylamine induces nerve cells apoptosis in
zebrafish mediated by depression of LSD1 activity. Brain Res Bull 80, 79-84,
(2009).

214

Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449,
105-U180, (2007).

215

Kontaki, H. & Talianidis, I. Lysine Methylation Regulates E2F1-Induced Cell
Death. Molecular Cell 39, 152-160, (2010).

216

Singh, M. M. et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone
deacetylase inhibitors. Neuro Oncol 13, 894-903, (2011).

217

Ame, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays
26, 882-893, (2004).

218

D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G. G. Poly(ADP-ribosyl)ation
reactions in the regulation of nuclear functions. Biochemical Journal 342, 249268 (1999).

134

219

Krishnakumar, R. & Kraus, W. L. The PARP Side of the Nucleus: Molecular
Actions, Physiological Outcomes, and Clinical Targets. Molecular Cell 39, 8-24,
(2010).

220

Saleh-Gohari, N. et al. Spontaneous homologous recombination is induced by
collapsed replication forks that are caused by endogenous DNA single-strand
breaks. Molecular and Cellular Biology 25, 7158-7169, (2005).

221

Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors
of poly(ADP-ribose) polymerase. Nature 434, 913-917, (2005).

222

Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a
therapeutic strategy. Nature 434, 917-921, (2005).

223

Fong, P. C. et al. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from
BRCA Mutation Carriers. New Engl J Med 361, 123-134, (2009).

224

Ji, Y. B. A. & Tulin, A. V. The roles of PARP1 in gene control and cell
differentiation. Current Opinion in Genetics & Development 20, 512-518, (2010).

225

Kraus, W. L. Transcriptional control by PARP-1: chromatin modulation,
enhancer-binding, coregulation, and insulation. Current Opinion in Cell Biology
20, 294-302, (2008).

226

Kim, M. Y., Mauro, S., Gevry, N., Lis, J. T. & Kraus, W. L. NAD(+)-dependent
modulation of chromatin structure and transcription by nucleosome binding
properties of PARP-1. Cell 119, 803-814 (2004).

227

Wacker, D. A. et al. The DNA binding and catalytic domains of Poly(ADPRibose) polymerase I cooperate in the regulation of chromatin structure and
transcription. Molecular and Cellular Biology 27, 7475-7485, (2007).
135

228

Krishnakumar, R. et al. Reciprocal binding of PARP-1 and histone H1 at
promoters specifies transcriptional outcomes. Science 319, 819-821, (2008).

229

Caiafa, P., Guastafierro, T. & Zampieri, M. Epigenetics: poly(ADP-ribosyl)ation
of PARP-1 regulates genomic methylation patterns. FASEB J 23, 672-678,
(2009).

230

Lonn, P. et al. PARP-1 Attenuates Smad-Mediated Transcription. Molecular Cell
40, 521-532, (2010).

231

Rodriguez, M. I. et al. Poly(ADP-ribose)-dependent regulation of Snail1 protein
stability. Oncogene 30, 4365-4372, (2011).

232

Miki, Y. et al. A Strong Candidate for the Breast and Ovarian-Cancer
Susceptibility Gene Brca1. Science 266, 66-71 (1994).

233

Wooster, R. et al. Identification of the Breast-Cancer Susceptibility Gene Brca2.
Nature 378, 789-792 (1995).

234

Weston, V. J. et al. The PARP inhibitor olaparib induces significant killing of
ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116, 4578-4587,
(2010).

235

Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with
PARP inhibitors. Embo Molecular Medicine 1, 315-322, (2009).

236

Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP
inhibition: PARP1 and beyond. Nature Reviews Cancer 10, 293-301, (2010).

237

Lin, Y. & Zhou, B. Histone mimics: digging down under. Front. Biol., 1-6,
(2012).

136

238

Morgunkova, A. & Barlev, N. A. Lysine methylation goes global. Cell Cycle 5,
1308-1312, (2006).

239

Lee, Y. H. & Stallcup, M. R. Minireview: protein arginine methylation of
nonhistone proteins in transcriptional regulation. Mol Endocrinol 23, 425-433,
(2009).

240

Egorova, K. S., Olenkina, O. M. & Olenina, L. V. Lysine methylation of
nonhistone proteins is a way to regulate their stability and function. Biochemistry
(Mosc) 75, 535-548, (2010).

241

Singh, B. N. et al. Nonhistone protein acetylation as cancer therapy targets.
Expert Rev Anticancer Ther 10, 935-954, (2010).

242

Peng, L. & Seto, E. Deacetylation of nonhistone proteins by HDACs and the
implications in cancer. Handb Exp Pharmacol 206, 39-56, (2011).

243

Kelly, A. E. et al. Survivin reads phosphorylated histone H3 threonine 3 to
activate the mitotic kinase Aurora B. Science 330, 235-239, (2010).

244

Ruchaud, S., Carmena, M. & Earnshaw, W. C. Chromosomal passengers:
conducting cell division. Nat Rev Mol Cell Biol 8, 798-812, (2007).

245

Jeyaprakash, A. A., Basquin, C., Jayachandran, U. & Conti, E. Structural basis for
the recognition of phosphorylated histone h3 by the survivin subunit of the
chromosomal passenger complex. Structure 19, 1625-1634, (2011).

246

Tarakhovsky, A. Tools and landscapes of epigenetics. Nat Immunol 11, 565-568,
(2010).

247

Marazzi, I. et al. Suppression of the antiviral response by an influenza histone
mimic. Nature 483, 428-433, (2012).
137

248

Bergamaschi, A. et al. Molecular profiling and characterization of luminal-like
and basal-like in vivo breast cancer xenograft models. Molecular oncology 3,
469-482, (2009).

249

Blick, T. et al. Epithelial mesenchymal transition traits in human breast cancer
cell lines. Clinical & experimental metastasis 25, 629-642, (2008).

250

Hennessy, B. T. et al. Characterization of a naturally occurring breast cancer
subset

enriched

in

epithelial-to-mesenchymal

transition

and

stem cell

characteristics. Cancer research 69, 4116-4124, (2009).
251

Sarrio, D. et al. Epithelial-mesenchymal transition in breast cancer relates to the
basal-like phenotype. Cancer research 68, 989-997, (2008).

252

Storci, G. et al. The basal-like breast carcinoma phenotype is regulated by SLUG
gene expression. The Journal of pathology 214, 25-37, (2008).

253

Dong, C. et al. G9a interacts with Snail and is critical for Snail-mediated Ecadherin repression in human breast cancer. J Clin Invest 122, 1469-1486, (2012).

254

Dong, C. et al. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin
repression in breast cancer. Oncogene, (2012).

255

Peters, A. H. et al. Partitioning and plasticity of repressive histone methylation
states in mammalian chromatin. Molecular cell 12, 1577-1589 (2003).

256

Rea, S. et al. Regulation of chromatin structure by site-specific histone H3
methyltransferases. Nature 406, 593-599, (2000).

257

Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification:
patterns and paradigms. Nat Rev Genet 10, 295-304, (2009).

138

258

Cheng, X. & Blumenthal, R. M. Coordinated chromatin control: structural and
functional linkage of DNA and histone methylation. Biochemistry 49, 2999-3008,
(2010).

259

Shinkai, Y. & Tachibana, M. H3K9 methyltransferase G9a and the related
molecule GLP. Genes Dev 25, 781-788, (2011).

260

Gal-Yam, E. N. et al. Frequent switching of Polycomb repressive marks and DNA
hypermethylation in the PC3 prostate cancer cell line. P Natl Acad Sci USA 105,
12979-12984, (2008).

261

Lindroth, A. M. et al. Antagonism between DNA and H3K27 Methylation at the
Imprinted Rasgrf1 Locus. Plos Genetics 4, (2008).

262

Kondo, Y. et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation
independent of promoter DNA methylation. Nat Genet 40, 741-750, (2008).

263

Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the
all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med
18, 605-611, (2012).

264

Harris, W. J. et al. The Histone Demethylase KDM1A Sustains the Oncogenic
Potential of MLL-AF9 Leukemia Stem Cells. Cancer Cell 21, 473-487, (2012).

265

Spannhoff, A., Hauser, A. T., Heinke, R., Sippl, W. & Jung, M. The Emerging
Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors.
Chemmedchem 4, 1568-1582, (2009).

139

VITA
Yiwei Lin
Date of Birth: November 11, 1980
Place of Birth: Zhangzhou, Fujian, China
Education:
Xiamen University, China, 1999-2006
B.S. Biology (2003)
M.S. Cell Biology (2006)
University of Texas Medical Branch at Galveston, 2006-2010
University of Kentucky, 2010-Present
Awards:
Department of Defense (DOD) Breast Cancer Predoctoral Traineeship Award (2010)
Publications:
Yiwei Lin, Chenfang Dong, Binhua P. Zhou. Epigenetic regulation of EMT: the Snail
story. Current Pharmaceutical Design. Accepted.
Yiwei Lin, Binhua Zhou. Doxorubicin enhances Snail/LSD1-mediated PTEN
suppression in a PARP1-dependent manner. In submission.

140

Yiwei Lin, Binhua P. Zhou. Histone mimics: digging down under. Frontiers in
Biology (2012), 1-6.
Yiwei Lin, Yadi Wu, Junlin Li, Chenfang Dong, Xiaofeng Ye, Young-In Chi, B.
Mark Evers, Binhua P. Zhou. The SNAG domain of Snail1 functions as a molecular hook
for recruiting lysine-specific demethylase 1. The EMBO Journal (2010) 29, 1803-1816.
Yingwei Chen, Wenxin Luo, Jin Wang, Mingqiao Wang, Ying Gu, Yiwei Lin, Jun
Zhang, Ningshao Xia. Expression and activity analysis of chimeric antibody against HBV
preS1. Chinese Journal of Microbiology and Immunology (2007) 2, 167-171.
Shuizhen He, Yiwei Lin, Zizheng Zheng, Xiaocheng Wu, Jun Zhang, Ningshao Xia.
Screening of protein interacting with HEV by yeast two-hybrid from human leucocyte
cDNA Library. Chinese Journal of Virology (2006) 4.
Rushi Liu, Kunyu Yang, Jian Lin, Yiwei Lin, Zhihong Zhang, Jun Zhang, Ningshao
Xia. High-yield expression of SARS coronavirus nucleocapsid protein in methylotropic
yeast Pichia pastoris. World Journal of Gastroenterology (2004) 10(24), 3602-3607.

Professional Experience:
Research assistant, School of Life Sciences, Xiamen University (2003-2006)
Research assistant, University of Texas Medical Branch at Galveston (2006-2010)
Research assistant, University of Kentucky (2010-Present)

141

